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The increasing emergence of antimicrobial resistant bacteria worldwide is recognized as a 
severe threat to public health on a global scale. Without effective antimicrobial agents to treat 
bacterial infections, modern medicine will be set back several decades and deaths caused by 
bacterial infections will increase. The most widely used class of antimicrobials, is b-lactams, 
and the increase in resistance against β-lactams due to b-lactamases, and especially extended-
spectrum b-lactamases (ESBL) is a great concern. In this study, our aims were to determine the 
carriage rate of ESBL-producing E. coli and K. pneumoniae in a random population, and to 
investigate the population structure of ESBL-producing E. coli and K. pneumoniae isolates 
from both carriage- and clinical samples. The carriage isolates were obtained by screening of 
fecal samples from inhabitants in the Tromsø municipality, collected through the Tromsø-7 
population study, and the clinical isolates were obtained from the 2014 NORM collection of 
ESBL-producing E. coli and K. pneumoniae, isolated from blood cultures and urine in different 
hospitals in Norway during 2014. An additional aim was to determine the carriage rate of K. 
pneumoniae, irrespective of resistance, in the Tromsø population. 
 
Screening of fecal samples from inhabitants in the Tromsø municipality, showed the carriage 
rate of ESBL-producing E. coli and K. pneumoniae to be 3.2%.  We also found the carriage 
prevalence of K. pneumoniae, irrespective of resistance, to be 14.7%. 
 
Whole-genome sequencing (WGS), was used to determine the population structure of the 
ESBL-producing carrier strains and the ESBL-producing clinical strains. The genotypic 
characterization of the ESBL-producing E. coli isolates showed both the carrier strains and the 
clinical strains were dominated by ST131, with CTX-M-15 as the most prevalent ESBL. 
Genotypic characterization of the clinical K. pneumoniae strains, showed a dominance by 
ST307, also with CTX-M-15 as the most prevalent ESBL.  
 
Our results show the carriage rate of ESBL- producing E. coli and K. pneumoniae in Norway 
is lower compared to other countries. The populations of carriage strains of both E. coli and K. 
pneumoniae is, however, dominated by known high risk clones. We recommend further 
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Abbreviations 
AAC Aminoglycoside-modifying acetyltransferases 
AMR Antimicrobial resistance 
ATCC American Type Culture Collection 
BLC Blood culture 
CAZ Ceftazidime 
CIP Ciprofloxacin 
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Eucast European Committee on Antimicrobial Susceptibility Testing 
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K-res Norwegian National Advisory Unit on Detection of Antimicrobial 
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MALDI TOF MS Matrix assisted laser desorption ionization time of flight mass 
spectrometer 
MBL Metallo b-lactamase 
MDR Multidrug resistant 
MEM Meropenem 
MIC Minimal inhibitory concentration 
MLST Multi locus sequence typing 
MRSA Methicillin-resistant Staphylococcus aureus 
NGS Next generation sequencing 
NORM Norwegian surveillance system for antibiotic resistant microbes 
NS Narrow spectrum 
NSBL Narrow spectrum b-lactamase 
PBP Penicillin-binding protein 
PMF Peptide mass fingerprint 
PMQR Plasmid-mediated quinolone-resistance 
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SCC staphylococcal cassette chromosome 
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SXT Trimethoprim-sulfamethoxazole 
TZP Piperacillin-tazobactam 
WGS Whole genome sequencing 
 
 
Page 2 of 105 
 
1 Introduction 
Antimicrobial resistance (AMR) is by the World`s Heath Organization (WHO) considered to 
be one of the most severe threats to global public health in modern time [1]. Without effective 
treatment of bacterial infections the treatment situation will be set back several decades, 
meaning relatively common infections could potentially be fatal [1]. The increasing prevalence 
of antimicrobial resistant bacteria provides a severe cause for concern on a global scale. As an 
example, antimicrobial resistant Tuberculosis is emerging as a major cause of death globally, 
and WHO estimated 170 000 people died from antimicrobial resistant tuberculosis globally in 
2012 [2]. The exact numbers are near impossible to obtain as many of these cases are from 
countries without proper surveillance programs [2]. 
 
Because infections with antimicrobial resistant bacteria are much harder to treat, the 
consequences can be increased mortality, longer hospital stays for the individual patients and 
therefore also higher costs per patient [1]. Antimicrobial resistant bacteria are often categorized 
in three different classes, depending on the extent of their resistance [3]. Some isolates are 
multidrug resistant (MDR), meaning they demonstrate resistance to agents belonging to three 
different antimicrobial classes [3]. Other isolates are classified as extensively drug resistant, 
meaning they express resistance to agents belonging to all but two of the different antimicrobial 
classes [3]. Some isolates even demonstrate resistance to all known antimicrobial agents, these 
are classified as pan-drug resistant [3]. 
 
On February 27th 2017, WHO published a priority list of antimicrobial resistant bacteria [4]. 
The purpose of this priority list was to set focus on resistant bacteria considered to be the most 
severe threat to public health, and to help coordinate a global research effort in the fight against 
antimicrobial resistant bacteria [4]. The resistant bacteria were divided into three categories: 
priority 1 (critical), priority 2 (high) and priority 3 (medium) [4]. Bacteria belonging to the 
family Enterobacteriaceae, resistant to carbapenems and/or third generation cephalosporins 
were categorized as critical, along with carbapenem-resistant Acinetobacter baumannii and 
carbapenem-resistant Pseudomonas aeruginosa [4]. 
 
In May 2016, Review on Antimicrobial Resistance published an extensive report on the 
prospects on the effects of AMR [5]. The work on this report was led by economist Jim O`Neill 
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and the report is therefore often referred to as “the O`Neill report” [5]. One of the stipulated 
alarming scenarios described in this report was the increase in annual deaths caused by AMR 
from 700 000 people globally in 2014, to 10 million people in 2050, unless action is taken [5]. 
This report points out certain areas where the authors recommend efforts should be made. 
Among these areas is increase of public awareness, improved focus on hygiene and sanitation, 
improved global surveillance of AMR and use of antimicrobial agents, and intensify research 
on antimicrobial resistant bacteria and the development of new antimicrobial agents [5].  
 
1.1 Antimicrobial agents 
The discovery of antimicrobial agents is without a doubt one of the major triumphs in modern 
medicine [6]. The ability to suddenly treat previously incurable infections, like syphilis, had an 
enormous impact on both healthcare and social life in the 1940`s [6]. It all started in 1928 with 
Alexander Fleming`s discovery of the inhibitory effects of the mould Penicillium notatum on 
colonies of Staphylococci growing on an agar plate [7, 8]. After some difficulties, the active 
substance was isolated in 1940 by Howard Florey and Ernest Chain [9]. The drug was called 
penicillin [7]. This was the starting point of  “the antibiotic era”, and Fleming, Florey and Chain 
received the Nobel Prize in 1945 for their work with penicillin [7]. In his acceptance speech, 
Fleming warned against misuse of the drug, claiming it would cause the emergence of resistant 
bacteria [10]. Since the discovery and further development of penicillin, a large number of 
different antimicrobial classes have been discovered [6]. Figure 1 illustrates the timeline of 
development of the major antimicrobial classes [6]. 
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Figure 1: Timeline showing the development of different antimicrobial classes by decade of introduction. (figure 
modified from [6]). 
 
1.2 Mechanisms of action of antimicrobial agents 
Today more than 20 different classes of antimicrobial agents have been discovered, each of 
these classes comprise of different specific compounds [11]. Some classes are extensively 
developed with a large number of different specific antimicrobial agents, while some classes 
only consist of a few different drugs [12]. All antimicrobial agents work by a specific 
mechanism of action. In general, there are four different main mechanisms by which 
antimicrobial agents can kill or inhibit growth of bacteria; inhibiting cell-wall synthesis, 
hindering protein synthesis, interfering with metabolic processes in the bacterial cell, or 
inhibition of DNA or RNA synthesis [13]. 
 
Maintenance and production of the bacterial cell wall is paramount for the survival of the 
bacterium [13]. An important feature of the cell wall is the peptidoglycan layer which consists 
of disaccharide subunits (N-acetylglucosamine and N-acetylmuramic acid) crosslinked to one 
another with peptide bridges [13]. Penicillin-binding proteins (PBPs) are bacterial enzymes 
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anchored in the cell membrane, which are essential for cell wall synthesis [13]. Antimicrobial 
agents targeting these enzymes, will inhibit the synthesis of peptidoglycan and the cell will 
succumb due to instability of the cell wall [13]. There are two main classes of antimicrobial 
agents targeting the cell wall synthesis, the β-lactams and the glycopeptides [13]. The largest 
class is the β-lactams, named by the β-lactam ring in the core of their molecular structure [13]. 
The β-lactams will be discussed in more detail in the next chapter. The other major class of cell 
wall targeting antimicrobial agents are the glycopeptides [13]. Agents belonging to this class 
does not bind to PBPs directly, but instead to precursors that are being incorporated into the 
cell wall by PBPs [13]. This inhibits the assembly of the cell wall and results eventually in cell 
lysis [13]. Glycopeptides are effective against most Gram-positive bacteria, and the most 
commonly used agent is vancomycin [12, 13]. 
 
Another antimicrobial target is the protein synthesis process of the bacterial cell [13]. The 
antimicrobial agents bind to either the 30S or the 50S ribosomal subunit, thereby inhibiting 
crucial steps in the protein synthesis [13]. Antimicrobial agents belonging to the two major 
classes aminoglycosides and tetracyclines, binds to the 30S subunit, inhibiting the ribosome 
translating mRNA [12]. Aminoglycosides have especially good antimicrobial activity against 
Gram-negative bacteria, while tetracyclines have good activity against many Gram-negative 
and Gram-positive bacteria [12]. Antimicrobial agents belonging to the major classes 
lincosamides and macrolides, also interfere with the protein synthesis, but these agents bind to 
the 50S subunit of the ribosome and prevent the elongation of peptide chains during protein 
synthesis [12]. Lincosamides have good antimicrobial activity against Gram-positive cocci, 
while macrolides work on most Gram-positive and some Gram-negative bacteria [12]. 
 
Some antimicrobial agents interfere with metabolic processes important for the bacterial cell, 
like the metabolism of folic acid, a metabolic pathway where the end products are precursors 
necessary for the DNA synthesis [13]. This particular process is inhibited by two different 
classes of antibiotics; sulphonamides and trimethoprim [13]. Sulphonamides bind to an enzyme 
involved in the folic acid pathway, dihydropteroate synthase, and consequently disrupt the 
pathway [13]. Trimethoprim function much in the same way, but binds to another enzyme in 
the pathway, dihydrofolate reductase (DHFR) [13]. Both these antimicrobial classes have 
activity against many Gram-positive and Gram-negative bacteria [13]. Trimethoprim-
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sulfamethoxazole is a combination drug which consist of both agents, and therefore inhibits the 
same metabolic process in two different places in the pathway, which makes it effective against 
a wider range of bacteria [13]. 
 
Several antibiotic classes work by inhibition of DNA and RNA synthesis [13]. 
Fluoroquinolones, for instance, bind to DNA gyrase, an enzyme that is involved in regulation 
of supercoiling of DNA which is essential for DNA replication, and thus inhibit DNA synthesis 
[13]. The activity spectrum of fluoroquinolones varies by the specific agent in question [12]. 
Narrow spectrum agents like nalidixic acid work against a number of Gram-negative bacteria, 
but are ineffective against Gram-positive bacteria, while broad-spectrum agents like 
ciprofloxacin have excellent effect against many Gram-negative and Gram-positive bacteria 
[12]. Rifampicin is another antimicrobial class with a similar mode of action [13]. It binds to 
the RNA polymerase and interferes with mRNA synthesis [13]. Rifampicin is active against 
many Gram-positive and Gram-negative bacteria [12]. Metronidazole is another antimicrobial 
agent inhibiting the DNA synthesis. This agent inflicts direct damage to the bacterial DNA by 
generating highly cytotoxic compounds or free radicals that ruptures the DNA [12]. 
Metronidazole displays activity against most anaerobic bacteria [12] 
 
Table 1 gives an overview of some of the most common antimicrobial classes, their target and 
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Table 1: Overview of selected common antibiotic classes, presented with bacterial target and examples of specific 
antibiotic agents [12, 13]. 
Examples of antibiotics  Antibiotic class  Target 
Penicillin G, penicillin V, ampicillin, 















cefazolin, cefadroxil, cephalexin, 
cephadrine 
1. gen.   
 
Cephalosporins cefuroxime, cefamandole,  





cefepime, cefpirome 4. gen. 
ceftaroline 5. gen. 




Sulbactam, tazobactam, clavulanic acid ß-lactamase 
inhibitors 
Vancomycin, teicoplanin Glycopeptides 
Gentamicin, amikacin, tobramycin, 
streptomycin 
Aminoglycosides S30 subunit  
Protein synthesis 
Doxycycline, tetracycline, tigecycline Tetracyclines 
Clindamycin, lincomycin Lincosamides S50 subunit 
Erythromycin, azithromycin Macrolides 
Ciprofloxacin, norfloxacin Fluoroquinolones DNA synthesis 
Sulfamethoxazole Sulfonamides Folic acid synthesis 
Trimethoprim DHFR inhibitor 
Metronidazole DNA damage 
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1.2.1 b-lactams 
As mentioned in the previous chapter, b-lactams comprise of a b-lactam ring in the core of their 
molecular structure [13]. b-lactams function as bactericidal drugs by binding to PBPs in the 
bacterial cell wall [14]. Different species of bacteria have different sets of PBPs, and each cell 
can have from three to eight different types of PBPs [14]. Different b-lactams have different 
affinity for different types of PBP [14]. Due to the diversity of PBPs among different bacterial 
species, the general activity spectrum of b-lactams is also diverse, meaning some b-lactams 
work best on Gram-positive bacteria, while others work best on Gram-negative [14]. The most 
important PBPs in Gram-negative bacteria is PBP1a, PBP1b, PBP2 and PBP3 [14].  
 
b-lactams is a vast class of antimicrobial agents, comprised of several subclasses, like 
penicillins, cephalosporins, carbapenems and monobactams, each with a large number of 
different derivatives evolved through history [13]. Every discovery of a new class of b-lactams 
or a specific agent, has been made out of necessity caused by resistant bacteria or a need to 
produce antimicrobial agents that would work on a broader selection of bacterial species [14].  
 
Penicillin, the first antimicrobial agent on the market, was a b-lactam. The first penicillins 
(benzylpenicillin and phenoxymethyl penicillin) were active against most Gram-positive 
bacteria, but had little effect on most Gram-negative bacteria [15]. In the 1950`s penicillin-
resistant Staphylococci started to emerge due to isolates producing penicillinase (a penicillin 
hydrolysing enzyme belonging to the b-lactamase family, discussed further in chapter 1.3.3), 
and in the early 1960`s, penicillinase-stable penicillins; methicillin and cloxacillin, were 
introduced [15]. Most of these penicillins were less active against Gram-negative bacteria, and 
there was a necessity to develop more broad-spectrum drugs to treat infections caused by these 
bacteria [15]. Examples of these broader spectrum penicillins, are ampicillin, amoxicillin and 
piperacillin [15].  
 
The first cephalosporin (cephalosporin C) was actually discovered in 1948, and exhibited a 
broad-spectrum of activity, but it`s effect was seemingly very low [15]. However, it was later 
discovered the molecule was more stable than penicillin, so it could be produced semi-
synthetically, which made it easier to manufacture larger amounts of the drug [15]. The first 
cephalosporin on the market, cephaloridine, was introduced in 1964, and several more 
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derivatives was developed during the 1960`s and 1970`s, like cephalexin and cephapirin [15]. 
These were the first generation cephalosporins, and they had effect on a large number of Gram-
positive bacteria, including penicillinase-producing Staphylococci, and some Gram-negative 
bacteria, like Escherichia coli and Klebsiella pneumoniae [15]. The basic molecular structure 
of cephalosporins was relatively easy to modify, and in the 1970s the second generation of 
cephalosporins was introduced with cefamandole in 1973 [15]. Furthermore, cefaclor was 
introduced in 1976 and cefuroxime in 1984 [15]. These second generation drugs had activity 
against a wider spectrum of Gram-negative bacteria, but less activity against Gram-positive 
bacteria [15]. The third generation of cephalosporins surfaced in the late 1970s, with the 
introduction of drugs like cefotaxime and ceftazidime [15]. The third generation cephalosporins 
were a solution to a growing problem with bacteria resistant to previous generations of 
cephalosporins, caused by b-lactamase production [15]. These new generation drugs had a 
limited spectrum of activity against Gram-positive bacteria, but worked better against Gram-
negative bacteria compared to the previous generations, including b-lactamase producing 
strains [15]. In the late 1980s a fourth generation of cephalosporins was developed [15]. This 
generation consisted of drugs like cefpirome and cefepime, which had even better activity 
against Gram-negative bacteria, and was considered to have an increased stability against the 
effect of b-lactamases [15]. A fifth generation cephalosporin, ceftaroline, was introduced in 
2010 [16]. This cephalosporin is termed “anti-MRSA cephalosporin” and it was produced as a 
solution to the rising problem with methicillin-resistant S. aureus (MRSA) [15]. This drug had 
extensive activity against Gram-positive bacteria compared to the previous generations of 
cephalosporins, including MRSA isolates [15]. Cephamycins, is another group of b-lactams 
often classified with second generation cephalosporines, as the antimicrobial spectrum of 
cephamycins are similar to that of second generation cephalosporines [15]. Cephamycins are 
however, much more stable against b-lactamases, including some of the extended-spectrum b-
lactamases [15]. In general cephamycins are stable towards class A extended-spectrum b-
lactamases, but less so towards class C b-lactamases (the different classes of extended-spectrum 
b-lactamases are explained further in chapter 1.3.3) [15]. An example of a common 
cephamycin, is cefoxitin [15]. 
 
In the late 1970s studies into a new class of b-lactams, carbapenems, were executed [15]. These 
compounds had a wider spectrum of activity compared to all previously known β-lactams and 
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were additionally very effective as b-lactamase-inhibitors [15]. The first generation of natural 
carbapenems were rather unstable and only functional when combined with an inhibitor of 
natural enzymes present in the human body [15]. The first synthetically manufactured 
carbapenem was imipenem, this drug also had to be combined with an inhibitor  not to be 
decomposed by enzymes in the human body [17]. The first carbapenem not dependent on an 
inhibitor of human enzyme activity, was meropenem, soon followed by others, like ertapenem 
and doripenem [15]. Due to the antimicrobial potency of carbapenems, and their effect on b-
lactamase producing bacteria, these drugs are considered to be the last-resort treatment of 
patients with severe infections caused by antimicrobial resistant bacteria [17]. 
 
Monobactams is another class of b-lactams, first discovered in the early 1980s, these agents 
had a limited activity spectrum, with no activity against Gram-positive bacteria, but exhibited 
good activity against Gram-negative bacteria [15, 18]. In 1983, the agent most widely used  
monobactam, aztreonam, was introduced as an agent for use against Gram-negative bacteria 
[15]. 
 
The most prevalent reason for AMR to b-lactams, is the production of bacterial b-lactamases, 
making the drug ineffective [15]. To address this problem, some b-lactams were combined with 
b-lactamase-inhibitors to form a combination drug with effect against bacteria known to 
produce b-lactamases [15]. An example of these combination drugs is amoxicillin-clavulanic 
acid, which had improved effect against b-lactamase producing Gram-positive and Gram-
negative bacteria [15]. Tazobactam is another inhibitor of b-lactamases and is combined with 
piperacillin to form the drug piperacillin-tazobactam [15]. 
 
In general, β-lactams are widely used, due to the wide selection of different agents, their 
bactericidal effect and their low toxicity to humans [13]. According to the NORM (Norwegian 
surveillance system for antibiotic resistant microbes) report published in 2015, β-lactams is the 
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1.3 Antimicrobial resistance 
 
Already before penicillin was introduced as a treatment option, resistance to the drug had been 
observed among some Staphylococcus strains, and in the late 1940`s, penicillin resistant 
bacteria were becoming a fast growing problem [20]. Several new β-lactams were introduced 
as a solution to the problem, but reports of resistance typically followed a few years later [20]. 
For instance, in 1960 the β-lactam methicillin was introduced, and in 1962 methicillin-resistant 
Staphylococci emerged [20]. In 1985 imipenem was introduced as a last resort treatment option 
for infections caused by highly resistant strains, and in 1998 there were reports of imipenem 
resistant Enterobacteriaceae [20]. 
 
The annual report published by the European antimicrobial resistance surveillance network 
(EARS-Net), reports of high, and increasing, levels of resistance in Gram-negative bacteria in 
many parts of Europe, and the situation is defined as “especially worrying” [21]. Many of these 
isolates were also multidrug-resistant, displaying non-susceptibility to third-generation 
cephalosporins, fluoroquinolones and aminoglycosides [21]. Figure 2 shows an overview of E. 
coli isolates with combined resistance to third-generation cephalosporins, fluoroquinolones and 
aminoglycosides in Europe in 2015 [21]. As shown in figure 3, the same multidrug-resistance 
is much higher in K. pneumoniae isolates, where some countries report a prevalence of more 
than 50% [21]. 
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Figure 2: Percentage of invasive E. coli isolates with combined resistance to third-generation cephalosporins, 




Figure 3: Percentage of invasive K. pneumoniae isolates with combined resistance to third-generation 
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There is also an increase in the prevalence of carbapenem-resistant Enterobacteriaceae, 
especially for K. pneumoniae, with a mean of 6.2% in 2012 to 8.1% in 2015 [21]. Looking at 
individual countries, the prevalence varied from <1% to a staggering 61.9% in Greece in 2015 




Figure 4: Percentage of invasive K. pneumoniae isolates with resistance to carbapenems in European countries in 
2015. Figure retrieved from EARS-Net [20]. 
 
The AMR situation in Norway is closely monitored by NORM, which publishes an extensive 
report on the prevalence of AMR and the usage of antimicrobial agents in Norway each year 
[19]. These reports conclude there have been increases in resistance against many important 
antimicrobial agents the last decade [19]. For instance, the prevalence of E. coli and K. 
pneumoniae isolates resistant to third generation cephalosporins has increased from 3-6% from 
2003 to 2015 [19]. The prevalence of clinical E. coli isolates non-susceptible to gentamicin 
(aminoglycoside), have increased severely from a little over one percent in 2000, to 6.4 % in 
2015 [19]. Of these isolates, 40.3% were also resistant to third generation cephalosporins, 
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making them multidrug resistant, as previously presented through the European data from 
EARS-Net [19, 21, 22]. Klebsiella spp. isolates non-susceptible to aminoglycosides in Norway, 
has increased from 1.0% in 2012, to 2.8% in 2015 [19]. There is also an increase in E. coli 
isolates with resistance to ciprofloxacin, from 7.3% in 2013 to 9.4% in 2014 [19]. The 
prevalence of K. pneumoniae isolates resistant to fluoroquinolones seem to be stable at 3-4% 
[19].  
 
The prevalence of Enterobacteriaceae with reduced susceptibility to carbapenems are still low 
in Norway, but the number of clinical isolates has increased from only a few isolates in 2007, 
to over 30 in 2015 [19]. The most worrying development within this category is the 3-fold 
increase in isolates from 2014 to 2015 [19]. A similar increase in resistance to carbapenems is 
seen with clinical strains of Acinetobacter baumannii and Pseudomonas spp. as well, from a 
few isolates in 2004 to 22 isolates in 2015 [19]. However, the sudden increase in later years is 
not seen, instead these isolates seem to have a more steady increase over several years [19].  
 
The increase in AMR in these bacterial species, makes the overall treatment of bacterial 
infections more difficult due to the limited options of antimicrobial agents left to choose from 
[1]. When the first-choice drugs are ineffective, more broad-spectrum drugs are administered, 
which are often more expensive and likely to cause even more resistance [23]. The treatment 
of infections caused by resistant bacteria is more time consuming, which means the patient 
needs to be hospitalized for a longer period of time, which again equals higher costs per patient 
[5]. In addition, the general decrease of effective antimicrobial agents also cripple other medical 
fields, like cancer-treatment or surgery [5]. Cancer patients often undergo treatment that 
compromise their immune system, like chemotherapy, and without effective antimicrobial 
agents, this form of treatment is extremely risky [5].  
 
1.3.1 Mechanisms of AMR 
 
AMR is the direct consequence of different resistance mechanisms expressed by bacterial cells 
[24]. These mechanisms of resistance can be sorted into three main categories; the minimization 
of the antimicrobial agent inside the cell (either by decreased uptake through the cell membrane 
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or active efflux), alterations of the antimicrobial target and degradation or alteration of the drug 
by microbial enzymes [24]. 
 
Decreased uptake of antimicrobials through reduced permeability of the bacterial cell is caused 
by downregulation or modification of porin proteins in the bacterial cell membrane [24]. 
Hydrophilic antimicrobial agents (like b-lactams) are dependent on these porins as gateways to 
the intracellular environment [25]. Hydrophobic drugs (like macrolides and aminoglycosides) 
on the other hand can diffuse through the lipid bilayer to gain access to the interior of the cell 
[25]. The major outer-membrane porins of Enterobacteriaceae (OmpF and OmpC) are believed 
to be non-specific channels, where antibiotic agents pass through to access binding sites inside 
the bacterial cell [24]. Resistance to these antimicrobial agents can therefore be achieved by the 
downregulation or modification of these proteins to become more selective, which leads to 
reduced uptake of the drug [24]. An example of the loss of porins leading to resistance, is the 
OmpF porin in E. coli [24]. This is one of the most abundant porins in the outer membrane of 
E. coli [25]. In E. coli micF RNA (a small noncoding RNA), is responsible for the negative 
regulation of expression of OmpF [26]. This downregulation is triggered by the presence of 
antimicrobial agents, and can cause resistance to, for instance, β-lactams [26, 27]. 
 
Efflux is another way for the bacterial cell to increase the concentration of antimicrobial agents 
intracellularly [24]. This ejection of the drug is caused by efflux pumps, located in the cell-
wall, actively transporting antimicrobial agents out of the cell as soon as it enters through the 
cell membrane [24]. Many different efflux pumps have been described, with different substrate 
specificity [24]. Some efflux pumps only exports a very narrow-spectrum of substrates, while 
others transport a wide range of different substrates, these pumps are known as “multidrug 
resistance efflux pumps” (MDR) [24]. An example of an MDR efflux pump found in E. coli, 
among others, is the AcrAB pump, belonging to a family of MDR efflux pumps known as the 
resistance nodulation division (RND) family [24]. This efflux pump consist of three main 
structures, an inner-membrane protein, an adaptor protein in the periplasmic space and a third 
protein in the outer membrane [28]. This AcrAB pump has a substrate profile that includes 
tetracycline, chloramphenicol, β-lactams, novobiocin, fusidic acid, nalidixic acid and 
fluoroquinolones [29]. Most bacteria have chromosomal genes encoding efflux pumps, and 
high levels of resistance is linked to an overexpression of these pumps [24]. This overexpression 
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can be caused by mutations in genes responsible for regulating the gene expression of efflux 
pumps [24]. Some efflux pump genes have also been mobilized, from the chromosome to 
plasmids, which can be transferred between bacterial cells [24]. In 2007 a new plasmid-
mediated gene for an efflux-pump called QepA was identified in an E. coli isolate from Japan 
[30]. This efflux pump conferred resistance to fluoroquinolones [30]. 
 
Another resistance mechanism is alterations of antimicrobial targets, so that the antimicrobial 
agents cannot bind to the bacterial target [24]. These alterations are caused by mutations in the 
genes encoding this target [24]. It can be alterations of the target molecule itself, leading to 
reduced affinity for the antibiotic agent, or the addition of another chemical group that will 
function as protection for the primary binding site [24]. For instance, the acquisition of a gene 
belonging to the gene-family qnr, confers resistance to fluoroquinolones [24]. The qnr genes 
encode specific proteins (pentapeptide repeat proteins) that will bind to the antimicrobial target 
of fluoroquinolones (DNA gyrase) and thereby protect the bacteria from the effects of the drug 
[24]. Another possibility of target alterations, is the acquisition of another target, similar to the 
original [24]. An example of this target change is methicillin resistant Staphylococcus aureus 
(MRSA), where the original penicillin-binding protein, PBP (important for cell wall synthesis), 
is supplemented by another version, PBP2a [24]. If a β-lactam antibiotic binds to the original 
PBP, in order to inhibit its function, the bacterial cell will still have a functioning penicillin-
binding protein in PBP2a, and will not be affected by the β-lactam drug [24]. The production 
of this homologous protein is caused by the acquisition of a new gene, mecA or mecC [24]. 
These genes are located on a mobilized gene-element called staphylococcal cassette 
chromosome mec element (SCCmec) [24]. 
 
The direct inactivation of an antimicrobial agent can be caused by bacterial enzymes modifying 
the agent by the addition of a chemical group, or inactivating the agent by hydrolysis [24]. As 
an example, aminoglycoside-modifying acetyltransferases (AAC) is a group of enzymes with 
the ability to inactivate aminoglycosides by acetylation [31]. There are several types of AACs 
conferring resistance to different antimicrobials, like AAC(3)-II which confers resistance to 
aminoglycosides like gentamicin and tobramycin, and AAC(6)-Ib which additionally confers 
resistance to fluoroquinolones [31]. The first antimicrobial hydrolysing enzyme ever described, 
was a penicillinase in 1940 [24]. Since then a large number of different enzymes have been 
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discovered [24]. Today thousands of different enzymes able to degrade antimicrobial agents 
belonging to most of the major classes of antimicrobial agents, like b-lactams, aminoglycosides 
and macrolides have been discovered [24]. Enzymatic degradation of antimicrobial agents is 
within many bacterial species, including E. coli and K. pneumoniae the main cause of 
antimicrobial resistance to certain antibiotics [24]. The largest and most diverse class of these 
hydrolysing enzymes, are the β-lactamases [24]. This enormous class of enzymes can hydrolyse 
agents belonging to all the different groups of β-lactams [24]. The β-lactamases will be 
described further in chapter 1.2.3. 
 
Bacteria are also likely to express a combination of several different mechanisms, for instance, 
genes encoding b-lactamases can be found on the same plasmid as genes encoding AAC 
enzymes or efflux pumps [24]. This combination of different resistance mechanisms may result 
in resistance to many different antibiotic classes simultaneously within one bacteria, by 
definition making it multidrug resistant [24]. The production of several versions of each main 
mechanism is also common, like the production of different β-lactamases within one bacterial 
cell [24].  
 
1.3.2 Mechanisms of transfer of AMR 
Antibiotic resistance can be intrinsic within a bacterial species, meaning the mechanism is 
inherent in that particular genus or species and is passed on to the next generation of cells by 
vertical gene transfer [24]. Intrinsic resistance is typically a result of structural or functional 
features within this specific genus or species [24]. 
 
Acquired resistance on the other hand is when one or several resistance mechanisms are attained 
by chromosomal mutations or horizontal transfer of resistance-genes originating from another 
bacterial cell [24]. These genes can be implemented in the bacterial chromosome or in plasmids 
within the cell, the transfer of entire plasmids are also common [24]. Resistance genes can be 
acquired through mutations or horizontal gene transfer [24].  
 
A mutation is essentially a change in the nucleotide sequence of a gene [13]. This alteration can 
be limited to a single nucleotide, parts of a gene, an entire gene or several genes in combination 
[13]. Mutations can occur spontaneously, by a replication error for instance, they can be the 
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consequence of exposure to mutagens, like chemical factors, or the product of biological 
factors, like foreign DNA being introduced to the bacterial cell [13]. Such a mutation can result 
in a phenotypic change in the bacterial cell, sometimes giving the mutated cells an advantage 
[32]. For instance, if the mutation results in antimicrobial resistance against penicillins, the 
mutants will have a greater chance of survival in an environment with high exposure to 
penicillin [32]. Consequently, the mutants will then multiply and the new gene(s) will be 
implemented in the population [32]. For a mutation to be considered stable, it must have been 
passed on from one generation to the next as a part of the bacteria`s genetic makeup [13]. Due 
to the fact that a majority of all bacteria are haploid for most of their genes, and their short 
generation-time, mutations may arise very quickly, for instance as a result of antimicrobial 
treatment [32].  
 
Another way for bacteria to acquire resistance genes is through horizontal gene transfer, 
meaning transfer of genes from one cell to another, unlike vertical gene transfer of the entire 
genome from mother- to daughter-cell during replication [13]. There are three main 
mechanisms of horizontal gene transfer, transformation, transduction and conjugation [13].  
Transformation is the uptake of free fragmented DNA originating from another bacterial cell 
undergone lysis. After uptake, the foreign DNA fragments can be implemented in the genome 
of the recipient cell [13]. Many bacterial species are capable of uptake and integration of naked 
extracellular DNA fragments, for example Streptococcus pneumoniae and Haemophilus 
influenza [33]. There are indications that being exposed to antimicrobial agents, may induce 
the bacteria`s ability to execute uptake of DNA through transformation [33]. 
 
Transduction is the transfer of genetic material from one bacterial cell to another by 
bacteriophages [13]. During infection of a bacterial cell the bacteriophage integrate its own 
DNA into the bacterial chromosome, in order to use the bacterial replication systems to produce 
viral products [13]. When this process is completed, the bacteriophage cut the viral DNA from 
the bacterial chromosome and package the DNA in protein cases [13]. These packages of viral 
DNA may also contain fragments of the infected cell`s DNA [13]. The infected cell lyses and 
the bacteriophage is released and free to infect another bacterial cell [13]. When it then releases 
its DNA in the new cell, the bacterial DNA from the first infected cell is also integrated in the 
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new cell`s chromosome [13]. Mobile genetic elements can also be transferred through 
transduction [33].  
 
Conjugation is genetic transfer through cell-to-cell contact [13]. This contact is facilitated by a 
sex pilus originating from the donor cell, or surface adhesins [13]. This sex pilus makes an 
intercellular bridge between the donor and the recipient cell, enabling the transfer of genetic 
material [13]. The conjugation machinery is typically encoded by genes located on a mobile 
genetic element, like plasmids or transposons [33]. The DNA transferred from the donor cell 
can either be chromosomal or located on the same mobilized genetic elements [13]. To transfer 
chromosomal DNA through conjugation, the chromosome must first be mobilized [13]. This is 
done by synthesis of a new DNA strand which is transferred to the recipient cell, which in turn 
synthesise a complementary DNA strand [13].  
 
Transposons are transposable elements, meaning DNA sequences that have the ability to change 
location within the chromosome, a plasmid, or move between the two genetic elements [13]. 
The transposons consist of genes necessary for movement as well as genes encoding qualities 
like AMR [13]. 
 
Plasmids are closed, circular genetic elements, which vary greatly in size from one-two kilo 
bases to more than one mega base [13]. Plasmids typically contain genes important for 
replication or transfer of the plasmid, and genes encoding features that can give the bacteria 
advantages over others, like AMR genes [13]. Some plasmids are transferable by conjugation, 
this is usually initiated with the replication of the plasmid in the donor cell, and the original 
plasmid is then transferred [13]. Plasmids are highly associated with transfer of antimicrobial 
resistance genes between bacteria [33]. There are many known plasmids harbouring specific 
AMR genes, that have been successfully spread through different bacterial species and genus 
[34]. These AMR plasmids, can be divided into two main groups, narrow-host-range and broad-
host-range plasmids [34]. Narrow-host-range plasmids can usually only be conjugated to other 
cells within the same species, while broad-host-range plasmids have compatibility to different 
species of bacteria [34]. Narrow-host-range plasmids are usually belongs to incompatibility 
group F (IncF), while broad-host-range plasmids often belongs to incompatibility groups A/C, 
L/M or N [34]. IncF plasmids are highly associated with antimicrobial resistant E. coli [34]. 
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Plasmids belonging to this group are generally very diverse and varies in size from 50-200kb, 
and are known to hold a wide range of resistance genes to multiple classes of antimicrobial 
agents on the same plasmid [34]. Considering the magnitude of resistance genes that can be 
found on a single plasmid, and their potential for rapid spread through conjugation, it is obvious 
that these genetic elements play an immense part in the world-wide distribution of AMR. 
 
1.3.3 b-lactamases and b-lactamase mediated resistance 
The first β-lactamase was described in 1940 and derived from an E. coli isolate. This β-
lactamase was chromosomally encoded and categorized as an penicillinase as it hydrolysed 
penicillin [35]. In 1965 the first plasmid mediated β-lactamase, from a Gram-negative bacteria, 
was discovered in Greece, it derived from an E. coli isolated from blood culture [35]. This β-
lactamase was called TEM-1, and it was soon discovered in other Gram-negative bacteria as 
well [35]. Another plasmid-mediated  β-lactamase from E. coli and Klebsiella pneumoniae was 
also discovered around the same time, this one was called SHV-1 [35]. TEM-1 can hydrolyse 
penicillins and first generation cephalosporins, also referred to as narrow-spectrum (NS) 
cephalosporins, while SHV-1 confers resistance to broad-spectrum  penicillins (for example 
ampicillin and piperacillin)[36]. As an answer to the emerging problem with β-lactamase 
producing bacteria, new antibiotic agents that were considered to be β-lactamase stable were 
developed, like second generation cephalosporins [35]. Subsequently, new variants of the 
known β-lactamases were identified, like TEM-3 and SHV-2, and these new variants had the 
ability to hydrolyse the new extended-spectrum (ES) β-lactams [35]. Consequently, these 
improved enzymes were categorized as “extended-spectrum β-lactamases” or ESBLs [35]. 
Since the discovery of the TEM and SHV enzyme families, a large number of other β-lactamase 
families have emerged in Gram-negative bacteria, like CTX-M, PER and OXA [36].  
 
CTX-M is one of the most common families of b-lactamases found in Enterobacteriaceae [37]. 
CTX-M genes are proven to have been transferred into Enterobacteriaceae from different 
species of Kluyvera  [37]. Due to bacterial evolution, this large b-lactamase family today 
comprise of over hundred different enzymes [37].  
 
The OXA family consists of a large number of extremely diverse enzymes with varying activity 
spectrum [38]. All OXA enzymes are oxacillinases, meaning they hydrolyse oxacillin, in 
 
 
Page 21 of 105 
 
addition, some are extended-spectrum OXAs (ES-OXA) and also exhibits activity against 
cephalosporins, and some are OXA-carbapenemases, hydrolysing carbapenems as well [38].  
 
The emergence of b-lactamases able to hydrolyse carbapenems has been of great concern seeing 
as carbapenems have been the antibiotic agents of choice when dealing with infections caused 
by ESBL producing bacteria [39]. The first carbapenemases discovered in the late 1980`s were 
chromosomally encoded, but soon other plasmid-mediated carbapenems were discovered, like 
KPC in K. pneumoniae [39]. 
 
The diversity and complexity of the β-lactamase enzymes call for systemized classification 
schemes to maintain an overview of the different enzymes. Several classification systems are 
currently in use, some based on the enzymes molecular properties, some based on more 
functional and clinically practical properties [38]. The β-lactamases can be divided into two 
major structural groups of enzymes; serine β-lactamases and metallo β-lactamases [40].	Serine 
β-lactamases uses serine to hydrolyze the β-lactam antibiotics, while metallo β-lactamases are 
dependent on hydrolysis by a hydroxide ion, stabilized by two zinc ions [40, 41]. The different 
enzymes` phenotypic resistance profile varies greatly, both between the specific enzyme-
families and the individual enzymes [38, 41]. Another scheme for further classification of β-
lactamases based on each enzyme`s molecular structure, is the Ambler classification scheme, 
which consists of four different classes; A, B, C and D [38]. Class A includes both narrow-
spectrum β-lactamases (NSBL), like TEM-1, and extended spectrum β-lactamases (ESBL), like 
TEM-3, and carbapenemases, like KPC [38]. Class B includes all the metallo β-lactamases 
(MBL), like NDM [38]. Class C includes AmpC cephalosporinases and class D are the 
oxacillinases (OXA), which can be NSBL, ESBL and even carbapenemases (Carbap.) [38]. 
Figure 5 shows this classification with examples of different enzymes/enzyme families and 
their general activity spectrum against specific ß-lactam classes. 
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Figure 5: Classification of β-lactamases. Basic classification based on biochemical structures, and further using the 









As described in the previous chapter, the first ESBL enzymes were derivatives of previously 
narrow-spectrum b-lactamases, like the TEM and SHV enzyme family. TEM, SHV and CTX-
M all belong to Ambler class A, but the CTX-M enzymes are by far the most successful [37]. 
In the 1980-90s ESBLs belonging to the TEM and SHV families were the most dominating, 
but in 2000-2010 the CTX-M enzymes took over as the most prevalent ESBLs in 
Enterobacteriaceae [37]. The first CTX-M was discovered already in 1989 in Munich, Germany 
[37]. The enzyme was found in an E. coli strain displaying resistance against cefotaxime, 
isolated from an infant with otitis [37]. The enzyme was called CTX-M-1 (CTX being an 
abbreviation of cefotaxime, and the M standing for Munich) [37]. Since then, hundreds of 
different CTX-M enzymes have been discovered, belonging to five main groups, or clusters, of 
enzymes, CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25 (See table 2 for origins 
and examples of enzymes) [37]. In general, CTX-M enzymes gives phenotypic resistance to 3rd 
and 4th generation cephalosporins, and monobactams, they are generally inhibited by b-
lactamase inhibitors like clavulanic acid, tazobactam and sulbactam [37]. Many bacteria 
expressing a CTX-M ESBL, also demonstrates co-resistance, resistance against other 
antimicrobial agents, like aminoglycosides and fluoroquinolones [37]. This co-resistance is 
usually caused by the acquisition of plasmids harbouring an assortment of different resistance 
genes encoding different resistance mechanisms [42]. Plasmid-mediated quinolone-resistance 
(PMQR) genes are for instance often carried on the same plasmid as CTX-M-genes [42]. 
 
The most successful CTX-M enzyme is without a doubt CTX-M-15, belonging to the CTX-M-
1 group [37]. This enzyme was first discovered in Enterobacteriaceae isolates in India in 1999, 
but soon spread to other continents [37, 43]. In 2001 CTX-M-15 emerged in the United 
Kingdom and during the following five years, CTX-M-15 producing E. coli strains were 
responsible for several outbreaks [37, 44]. The majority of these isolated strains were later 
proved to belong to sequence type 131 (ST131) [44]. This specific E. coli clone will be 
discussed further in chapter 1.4.1.2. Bacteria producing CTX-M-15 disseminated rapidly, and 
it is now the most prevalent CTX-M enzyme in the world [37]. Different CTX-M enzymes 
seem to have arisen in different geographical areas, like CTX-M-10 mainly described in Spain 
and France, and CTX-M-14 in Korea, but then spread to other regions [37]. As mentioned, 
CTX-M-14 was first described in Korea in 1995 [37]. It then appeared in China in 1997, Taiwan 
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in 1998, France 1999 and in Brazil the same year [37]. This shows the enormous success of the 
CTX-M enzymes, and how fast bacterial populations can evolve, especially subjected to 
environments containing antimicrobial agents. The blaCTX-M genes are normally located on 
plasmids, which can be one explanation for the rapid spread of the CTX-M enzymes through 
conjugation [37]. The origin of the CTX-M enzymes were genes chromosomally located in 
different Kluyvera species, that became mobilized on mobile genetic elements, like plasmids 
(for details, see table 2) [37]. Carrying plasmids containing blaCTX-M became a significant 
advantage for the bacterial cell, and natural selection in a cephalosporin rich environment 
resulted in the success of CTX-M producing clones, like ST131 [37]. In addition to the sheer 
survival of these clones, international travel and immigration, along with the export of food 
products, are probably all factors in the international dissemination of these clones [37]. 
 
Table 2: The different CTX-M groups or clusters, with the origin of each of the groups and examples of specific 
CTX-M enzymes belonging to each group. (Based on Table 1 in “CTX-M enzymes: origin and diffusion” [37]) 
CTX-M group (cluster): Origin: Examples of CTX-M enzymes: 
CTX-M-1 Kluyvera cryocrescens  
(ancestral gene: kluC) 
CTX-M-1, CTX-M-3,  
CTX-M-15 
CTX-M-2 Kluyvera ascorbate  
(ancestral gene: kluA) 
CTX-M-2, CTX-M-44 
CTX-M-8 Kluyvera georgiana 
(ancestral gene: kluG) 
CTX-M-8 
CTX-M-9 Kluyvera georgiana 
(ancestral gene: kluY) 
CTX-M-9, CTX-M-14,  
CTX-M-24, CTX-M-27 
CTX-M-25 Kluyvera georgiana 
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1.4 Bacterial species 
This project targets two different bacterial species, E. coli and K. pneumoniae, both Gram-
negative bacteria belonging to the large family Enterobacteriaceae. This large and 
comprehensive bacterial family consists of at least several hundred species, and is steadily 
expanding due to the advances in technology, especially that of genomic analysis. Species 
belonging to this vast family range from species considered relatively harmless for humans, 
such as Aranicola proteolyticus and Buchnera aphidicola, to species well known to cause 
severe infections in humans, like Salmonella typhimurium and Shigella sonnei. [12] 
 
Species belonging to the Enterobacteraceae family are well known for causing hospital acquired 
infections, like ventilator associated pneumonia, blood stream infections, urinary tract 
infections and post-operative wound infections [45, 46].  
 
1.4.1 Escherichia coli 
E. coli is a common commensal species inhabiting the gut of humans and animals, but the 
species also have pathogenic potential and can therefore be labelled as an opportunistic 
pathogen [47]. E. coli is the main cause of urinary tract infections, but can also cause more 
severe infections if it gains access to sterile sites, like the bloodstream, and is proven to be the 
dominating cause of blood stream infections by Gram-negative bacteria [47]. According to the 
2015 NORM report, E. coli is the leading cause of all blood stream infections in Norway [37]. 
In 2015 32.4% of blood stream infections were caused by E. coli, while the second most 
common cause was S. aureus, which was responsible for 14.4% of the infections, when bacteria 
considered to be skin flora contaminants had been disregarded [37]. E. coli is also known to 
cause infections like meningitis, wound infections, osteomyelitis, etc. [47]. E. coli is also 
frequently associated with nosocomial infections like ventilator associated pneumonia, hospital 
acquired blood stream infections, surgical sites infections and nosocomial urinary tract 
infections [46].  
 
1.4.1.1 Antimicrobial resistance in E. coli 
As described in chapter 1.3, the prevalence of E. coli isolates with a wide selection of different 
acquired resistance-genes have increased over the last decades. The 2014 WHO report on 
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antimicrobial resistance shows a high level of antibiotic resistance in E. coli isolates worldwide 
[2]. Five of six world regions report 50% or more of  E. coli isolates to be antibiotic resistant 
[2].  
 
b-lactam resistance in E. coli is most frequently caused by the production of b-lactamases [48]. 
The E. coli chromosome holds the gene encoding an intrinsic AmpC β-lactamase, however, the 
gene is usually weakly expressed [48]. This expression of AmpC in E. coli is non-inducible, 
but can still be regulated by alterations in the promoter region and isolates producing high levels 
of AmpC have been identified in clinical samples [48]. Isolates like this will typically express 
phenotypic resistance to for example penicillins and some 2nd generation cephalosporins, like 
cefoxitin [48]. They can also express resistance to expanded-spectrum cephalosporins if the 
upregulation of the AmpC gene is extensive [48]. In addition to the chromosomally encoded 
AmpC β-lactamase, a large number of acquired β-lactamases have been identified in E. coli 
worldwide, this subject will be addressed in more details in the next chapter. 
 
In addition to the intrinsic AmpC b-lactamase, E. coli may also carry plasmid-mediated AmpC 
enzymes [49]. The most frequently found plasmid-mediated AmpC in E. coli, is CMY-2 [49]. 
The gene encoding this AmpC b-lactamase, blaCMY-2, is related to a chromosomally encoded 
AmpC gene in Citrobacter freundii [49]. The CMY-2 enzymes confer resistance to 1st, 2nd and 
3rd generation cephalosporins, and enhanced resistance to penicillins [49].  
 
The main cause of fluoroquinolone resistance in E. coli is mutations in the bacterial targets, 
DNA gyrase and topoisomerase IV (gyrA and parC), but other mechanisms are also 
represented, like reduced uptake in the cell due to loss or downregulation of porins or efflux 
mechanisms, like QepA [50]. Fluoroquinolone resistance can also be caused by pentapeptide 
proteins (Qnr proteins) protecting the bacterial targets, or fluoroquinolone-modifying 
aminoglycoside acetyltransferases (AAC(6)-Ib) which modify the drug [51].  
 
Aminoglycoside resistance in E. coli is mainly caused by the production of aminoglycoside 
modifying enzymes, like aminoglycoside acetyltransferases (ACC), modifying the 
aminoglycoside, or 16S rRNA methylases, which alters the binding site of 16S rRNA [52]. 
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Aminoglycoside resistance in E. coli can also be conferred by the upregulation of efflux pumps 
[53].  
 
The E. coli genome have in recent years been extensively studied, leading to a greater 
understanding of the species` genomic diversity [47]. The genome can be divided into two main 
parts. One consists of a core genome which has been conserved throughout the evolution [47]. 
The other main part is extremely flexible and consist of mobile genetic elements, like plasmids, 
bacteriophages, transposons and insertion sequence (IS) elements [47]. These mobile genetic 
elements may harbour genes encoding pathogenic properties or antibiotic resistance [47]. 
 
Analysis of the E. coli genome can yield important information which can be used to determine 
which clonal group the isolate belongs to, and compare it to other isolated strains [47]. These 
genomic progresses are extremely important epidemiological tools, for instance in outbreak 
surveillance [47]. 
 
1.4.1.2 ESBL-producing E. coli 
 
As mentioned in the previous chapter, CTX-M enzymes has arisen as the dominant ESBLs in 
E. coli [54]. Enzymes of the TEM and SHV family is still common, but CTX-M is today the 
most prevalent ESBL in E. coli [54]. CTX-M enzymes have been found in E. coli isolated from 
clinical samples (both nosocomial and community acquired), human carrier strains, animals 
(both production animals and pets), food products and from environmental samples like sewage 
[54]. Most prevalent of the CTX-M enzymes in E. coli, is CTX-M-15 [54]. The dissemination 
of this enzyme worldwide can be accredited to the rapid spread of E. coli ST131 [54]. This 
clonal group emerged in several different regions in 2008, more specifically in Canada, a few 
European countries (France, Spain, Portugal and Switzerland) and in four Asian countries 
(India, South Korea, Lebanon and Kuwait) [55]. Soon after it was also detected on the African 
continent and in Oceania, along with numerous other countries in America, Europe and Asia 
[55]. ST131 is today the predominant E. coli sequence type causing infections in humans [55, 
56]. E. coli ST131 isolates have an extensive repertoire of both virulence and antibiotic 
resistance genes [55]. As an example; most ST131 isolates possess blaCTX-M-15, encoding the 
production of the CTX-M-15 enzyme, making the bacteria resistant to penicillins, extended-
spectrum cephalosporins and monobactams [55]. In addition the same clonal linage is also 
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associated with co-resistance to fluoroquinolones [55]. A large number of plasmids of varying 
sizes, gene-content and incompatibility groups have been identified in different E. coli ST131 
strains, of these, IncF type plasmids are the most common [55]. Other E. coli clonal groups 
have also been associated with pathogenic significance, like ST648 and ST38 [54]. ST648 is 
also associated with the carriage of CTX-M-15, while ST38 is associated with CTX-M-9 [54]. 
Another clonal group associated with clinical samples, is ST405 [57]. Isolates belonging to this 
sequence type is known to produce CTX-M-15, and a carbapenemase called NDM-1 (New 
Dehli metallo-b-lactamase) has also been identified in ST405 strains [57].  
 
1.4.2 Klebsiella pneumoniae 
 
Klebsiella pneumoniae is known as an environmental bacterium, residing in habitats like soil 
and surface waters [58]. It is a known colonizer of mucosal surfaces of humans, especially the 
gastro intestinal tract and the oropharynx [58]. It is an opportunistic pathogen, and colonizing 
strains can cause infections in an immunocompromised host, like pneumonia, hospital acquired 
blood stream infections, post-operative wound infections, urinary tract infections and liver 
abscesses [58]. K. pneumoniae also has the ability to colonize artificial surfaces of medical 
devices, like urinary catheters and ventilator tubes due to the formation of biofilms [59]. Due 
to the opportunistic nature of K. pneumoniae causing infections in hospitalized patients and its 
ability to endure in hospital environments, it is well established as a nosocomial pathogen [60]. 
According to the 2015 NORM report, 9,1 % of blood stream infections in the participating 
hospitals in Norway in 2015, was caused by Klebsiella spp. once bacteria considered to be skin 
flora contaminants had been disregarded [37].  
 
In recent years, the advances in molecular analysis, and in particular the possibilities for whole 
genome sequencing, have resulted in the definition of three different phylogroups of K. 
pneumoniae; KpI, KpII and KpIII [61]. It has also been proposed that these phylogroups should 
be redefined as three different species; K. pneumoniae (KpI), K. quasipneumoniae (KpII) and 
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1.4.2.1 Antimicrobial resistance in K. pneumoniae 
 
As described in chapter 1.2, the emergence of K. pneumoniae clones showing increasing levels 
of antibiotic resistance has been a severe concern for the last decades [58]. As a result of this 
increasing resistance, treatment of infections caused by K. pneumoniae is consequently getting 
more difficult [58].  
 
The 2014 WHO report on antimicrobial resistance shows a general higher level of antibiotic 
resistance in K. pneumoniae isolates worldwide, compared to E. coli [2]. All six world regions 
report a resistance prevalence of 50% or more for K. pneumoniae isolates [2].  
 
The most prevalent cause of resistance against cephalosporins in K. pneumoniae is the 
production of b-lactamases [62]. K. pneumoniae (KpI) strains have a chromosomally encoded 
SHV b-lactamase, while all K.variicola and have a chromosomally encoded LEN b-lactamase, 
and K. quasipneumoniae harbours an intrinsic OKP b-lactamase [61]. The production of this 
b-lactamase usually occurs at low levels, but it still gives phenotypic resistance against 
penicillins like ampicillin, amoxicillin, ticarcillin and carbenicillin [63]. In addition, numerous 
acquired b-lactamases have been identified in K. pneumoniae, this will be discussed further in 
chapter 1.4.2.2.  
 
Fluoroquinolone resistance in K. pneumoniae can be caused by several different resistance 
mechanisms, like mutations or protection of the target molecule, downregulation of porins and 
increase in the production of efflux pumps [64]. Resistance can be adverse by a combination, 
and sometimes all these mechanisms in cooperation [64]. An example of target protection is 
the Qnr-proteins which are pentapeptide proteins that protects DNA gyrase and topoisomerase 
IV from the inhibitory effect of fluoroquinolones [64]. Genes encoding these proteins (qnr) are 
often found on plasmids [64].  
 
The most prevalent cause of aminoglycoside resistance in K. pneumoniae is the production of 
drug-modifying enzymes, for instance aminoglycoside acetyltransferases (ACC), which have 
been described previously in chapter 1.3.1, the genes for these enzymes are usually found on 
mobile genetic elements [31]. Another mechanism of resistance to aminoglycosides found in 
K. pneumoniae is the aminoglycoside-modifying enzyme 16S rRNA methyltransferase [65]. 
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This enzyme confers resistance to aminoglycosides by altering the binding site of 16S rRNA 
[65]. Other resistance mechanisms responsible for aminoglycoside resistance are loss or 
downregulation of porins and the production of efflux pumps [65]. 
 
1.4.2.2 ESBL-producing K. pneumoniae 
In addition to the intrinsic SHV-1 b-lactamase, a wide range of acquired b-lactamases have 
been discovered in K. pneumoniae isolates worldwide [66]. When ESBLs started to emerge, 
the most commonly encountered ESBLs in K. pneumoniae were mutants of TEM and SHV 
type enzymes, but as with E. coli, the CTX-M enzymes later took over as the dominating ESBLs 
in K. pneumoniae [62]. And as was the case with E. coli, CTX-M-15 has had enormous success 
in K. pneumoniae as well [62]. 
 
The 2014 WHO global report on antimicrobial resistance shows several world regions have a 
higher prevalence of K. pneumoniae isolates showing resistance to third generation 
cephalosporins, than E. coli isolates [2]. In fact, a large number of countries, belonging to all 
six WHO world regions, reported more than 50% of clinically isolated K. pneumoniae, was 
resistant to this group of antimicrobials [2].  
 
The advances in genomic methods, makes it easier to determine lineages of highly virulent or 
antibiotic resistant clones. The most infamous of these clones have, by MLST, been given the 
designation ST258 [61]. This sequence type was first described in 2009 [67]. Isolates belonging 
to this sequence type, often produces a KPC b-lactamase (carbapenemase), making the isolate 
resistant to penicillins, cephalosporins, monobactams and carbapenems [61].There are several 
other K. pneumoniae clones considered to have clinical importance, some of them will be 
briefly accounted for. K. pneumoniae ST17 was the main clone responsible for an outbreak in 
a neonatal intensive care unit at Stavanger university hospital in Norway in 2008-2009 [68]. 
This clone produced CTX-M-15 and TEM-1 [68]. K. pneumoniae ST11 is another clinically 
important clone associated with different CTX-M enzymes as well as KPC [69]. This clone is 
widespread in Asia and is the dominating clone associated with the dispersal of KPC producing 
K. pneumoniae in China [69]. K. pneumoniae ST307 is another clone known to produce a CTX-
M-15, and some strains even produce a KPC in addition. This clone has replaced ST258 as the 
most dominant K. pneumoniae clone associated with the spread of KPC in Italy [70]. Another 
 
 
Page 31 of 105 
 
K. pneumoniae sequence type associated with co-production of both CTX-M-15 and KPC, is 
ST340 [71]. This sequence type belong to the same clonal group (CG258) as ST258 and ST11 
[71]. 
 
1.5 Carriage of ESBL-producing E. coli and K. pneumoniae 
Both E. coli and K. pneumoniae is considered parts of the commensal intestinal flora in humans, 
it is therefore logical that among these commensal strains, there may be some which have 
acquired genes for ESBL production. Different studies undertaken in different countries and 
regions, show very diverse results when it comes to the community carriage of ESBL-producing 
E. coli and K. pneumoniae. In Norway, a study from Stavanger university hospital, showed a 
prevalence of fecal carriage of ESBL-producing Enterobacteriaceae to be 2.9% (n=26) among 
pregnant women (n=901) [72]. Another Norwegian study describing ESBL-producing 
Enterobacteriaceae carriage in patients with gastroenteritis (n=273) in 2014, showed a 
prevalence of 15.8% [73]. Another study done in Norway from 2016, determined the carriage 
rate of ESBL-producing Enterobacteriaceae in “healthy individuals” to 4.9% [74]. A French 
study from 2012 showed the carriage rate of ESBL-producing E. coli in individuals in the Paris 
area to be 4.9% [75]. The same study showed this prevalence was a 10-fold increase in five 
years [75]. A Swedish study from 2016 concluded with a community carriage rate of ESBL-
producing E. coli at 4.7% [76], and a Dutch study from the same year, showed a prevalence of 
ESBL producing Enterobacteriaceae of 8.6% [77]. An overview of these six studies is presented 
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Table 3: Selected studies investigating carriage rates of ESBL-producing Enterobacteriaceae 
  
On a global scale, a large review article by Woerther et al. was published in 2013, investigating 
studies on community fecal carriage of ESBL-producing Enterobacteriacea, from different 
world regions [78]. This review shows carrier rates in all regions were low (less than 10%) 
before 2008, but in some regions, increased rapidly after 2008 [78]. In 2008, the first incidence 
of carrier rates exceeding 60% was reported in Thailand [78]. This review also shows great 
difference between different world regions [78]. In Europe, the carrier rates were mostly limited 
to under 10% with little alteration from 2001 to 2011 [78]. The same seems to be the case for 
America, while for the Eastern Mediterranean, Western Pacific and South East Asia, the 
carriage rates have increased from under 10% to well over 60% in the same time period [78]. 
The review stipulates that in 2011 there were 1.1 billion community carriers in South East Asia, 
280 million in the Western Pacific region, 180 million in the Eastern Mediterranean, 110 
million in Africa, 48 million in America and 35 million carriers in Europe [78]. The same article 
pointed to international travelling as a risk factor for the acquisition of colonizing ESBL-
producing bacteria [78]. The highest acquisition rates seemed to be associated with travel to 
India, South-East Asia, Thailand and The Middle East [78]. The Norwegian study of ESBL-
carriage in patients with gastroenteritis also looked at possible risk factors for acquiring ESBL-
producing Enterobacteriaceae, and also concluded that travel to Asia was a significant risk 
factor [73]. 
Author: Year: Country: Population: Prevalence: 
Rettedal et al. [72] 2015 Norway Pregnant women (n=901) 2.9% 
Jørgensen et al.  [73] 2014 Norway Patients w/ gastroenteritis 
(n=273) 
15.8% 
Ulstad et al.  [74] 2016 Norway  Healthy individuals 
(n=284) 
4.9% 
Nicolas-Chanoine et al. 
[75] 
2012 France French inhabitants 
(n=345) 
4.9% 
Ny et al.  [76] 2016 Sweden  Swedish inhabitants 
(n=2134) 
4.7% 
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1.6 Carriage of K. pneumoniae 
Most studies of colonization of K. pneumoniae today are focused on isolates with specific 
resistance markers, like carbapenemase- or ESBL-producing K. pneumoniae. There are few 
studies concentrating on carriage of K. pneumoniae as a species, disregarding antimicrobial 
susceptibility. A few studies are presented in table 4. These four different studies range in 
prevalence from 21.1% to 62.1% [79-81]. The two oldest studies were carried out in 2012 in 
China and Korea [79, 80]. In both studies a similar amount of samples (954 and 1174) were 
taken from adult inhabitants and the prevalence rates were 21.1% for Korea and 62.1% for 
China [79, 80]. An American study, carried out in 2016, found a prevalence of 23% [81]. This 
study only included hospitalized patients, and the number of samples collected were 1765 [81]. 
The most recent of the selected studies was published in January 2017, and also included 
hospitalized patients admitted to an intensive care unit in an Australian hospital [82]. This study 
found a prevalence of carriage of 6% among patients admitted from the community, and 19% 
among patients whom had been recently hospitalized, total carriage rate of both populations 
was 10.4% [82]. 
 
Table 4: Selected studies investigating carriage rates of K. pneumoniae. 
 
Author: Year: Country: Population: Prevalence: 
Martin et al. [81] 2016 USA Hospital patients (n=1765) 23% 
Lin et al. [79] 2012 China Adult Chinese inhabitants 
and Chinese adults living 
in other Asian countries 
(n=954) 
62.1% 
Chung et al. [80] 2012 Korea Korean adults and foreign 
adults who are ethnic 
Koreans (n=1174) 
21.1% 
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2 Aim of the study 
The main aim of this study was to determine the population structure of ESBL-producing E. 
coli and K. pneumoniae isolates from both carriage- and clinical samples. In order to achieve 
this, three separate queries were addressed: 
• What is the carriage rate of ESBL-producing E. coli and K. pneumoniae among 
individuals in Tromsø? 
• What is the population structure of ESBL-producing E. coli and K. pneumoniae in 
clinical isolates and in community carriers? 
 
An additional query was also included in the project as it proceeded: 
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3 Materials and methods 
3.1 Sample collection 
 
To achieve the aims of this study, several bacterial samples had to be obtained. Fecal samples 
from individuals in Tromsø was used to determine the carriage rate of K. pneumoniae, and the 
prevalence of ESBL-producing E. coli and K. pneumoniae, as well as the population structure 
of the latter. To determine the population structure of ESBL-producing E. coli and K. 
pneumoniae in clinical isolates, ESBL producing E. coli and K. pneumoniae isolated from urine 
and blood cultures were obtained through NORM. 
 
3.1.1 Fecal samples from Tromsø-7 
The Tromsø Study is a series of large population studies carried out in Tromsø over a 40-year 
time span [83]. The first Tromsø Study, Tromsø-1, was carried out in 1974 [83]. This first study 
targeted cardiovascular diseases, and compiled data from 6595 men [83]. Since then, six more 
extensive studies have been completed, gathering data for research of a wide range of medical 
and social fields of interest [83]. 
 
Tromsø-7 is the latest of these population studies, carried out in 2015-2016, and collecting data 
for a large number of different research projects, such as cancer, obesity, mental health, diabetes 
and antimicrobial resistance [84]. In total, 33 423 men and women over the age of 40, were 
invited to participate in the study [84]. The study was composed of two main parts. Part one 
was a general health survey accompanied by several questionnaires, 21 083 men and women 
participated in this first part of the study [84]. A selection of 9000 individuals were also invited 
to participate in the second part of the study, which composed of more extended and specialized 
surveys [84]. As a part of this survey, 6358 participants were asked to deliver a fecal sample in 
order to study the carriage of antimicrobial resistant bacteria in the random population [84]. 
From these individuals, a total of 5015 fecal samples were collected [84]. Further details on the 
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3.1.2 Bacterial isolates from NORM 
Norwegian surveillance system for antibiotic resistant microbes (NORM) is a health register 
for data on resistant microbes in Norway [85]. Every year specific isolates are collected from 
Norwegian clinical microbiology laboratories and the statistical data from these isolates are 
used as a basis for monitoring the occurrence and spread of resistant microbes throughout the 
country [85]. This yearly surveillance serves as an effective tool to assess the development of 
antimicrobial resistance over time [85]. 
 
The data collected through NORM is also reported further internationally to the European 
Antimicrobial Resistance Surveillance Network (EARS-Net), who summarizes data from 29 
European countries [21]. 
 
In this project, 126 ESBL-producing E. coli and 39 ESBL-producing K. pneumoniae isolated 
from blood cultures in 2014 originated from different hospitals in Norway, were analyzed using 
whole-genome sequencing to examine the population structure, ESBL-variant and other 
resistance genes. Results from susceptibility testing of these isolates along with results from 
1243 non-ESBL producing K. pneumoniae collected in 2014, was also retrieved from NORM 
for comparison [22]. Table 5 shows a complete overview of the different isolates included in 
this project. 
 
Table 5: Table showing specifications for all the bacterial isolates included in the project with the source of collection, 
type of sample and number of isolates. (*) The non-ESBL producing K. pneumoniae from NORM 2014 were not 
analyzed during this project. Previously registered data was used for comparison purposes. 
Collected 
through: 
Species: No. of isolates: Sample origin: 
Tromsø-7 
(Carrier strains) 
ESBL-producing E. coli 23 Faeces 
ESBL-producing K. pneumoniae 2 Faeces 
K. pneumoniae 97 Faeces 
NORM 2014 
(Clinical strains) 
ESBL-producing E. coli 126 Blood culture 
(n=90) 
Urine (n=36) 
ESBL-producing K. pneumoniae 39 Blood culture 
(n=24) 
Urine (n=15) 
Non-ESBL producing K. 
pneumoniae* 
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3.2 Cultivation of bacteria (Tromsø-7 study) 
ESBL-producing E. coli and K. pneumoniae (both ESBL-producing and non-ESBL-producing 
strains) was isolated from 662 fecal samples from individuals participating in the Tromsø-7 
study. The cultivation was performed using different selective and differentiating growth media 
as described below.  
 
3.2.1 Screening of Tromsø-7 samples 
The fecal samples had been prepared in ESwab tubes (Copan) by each of the individuals from 
whom it came. All the selected participants had received a kit containing an ESwab tube with 
a sterile swab for sample collection, gloves, a label with a unique identification number, a return 
envelope and description of how to collect and prepare the sample. 
 
The following procedure was presented to the participants: 
1. Open the packaging containing the ESwab tube. Make sure the swab does not come in 
contact with any surfaces. 
2. Rub or roll the end of the swab in toilet paper with faeces. There should be visible 
faeces on the swab. 
3. Open the ESwab tube and place the swab into the tube. 
4. Break the swab at the red mark, and put the lid on the ESwab. 
5. Place the label on the tube, place the tube in the return envelope and send or deliver the 
sample to “Tromsøundersøkelsen”.  
 
Upon arriving to the laboratory, each of the E-swab tubes had been given an internal laboratory 
identification number, and 200µl 85% glycerol (Merck) was added before they were frozen at 
-70°C.  
 
To administrate the screening process of the fecal samples, the laboratory information system 
(LIS) CGM Analytix, version 5.12, (CGM) was used. The system does not have separate 
modules designated for research purposes and therefore had to be configured for this purpose. 
A unique registration code (T7-DYRK-PR) was created and the four different agars used in the 
project was linked to the registration code. In addition, a new freezing system had to be 
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implemented to cope with the large number of isolates to be frozen, as well as refreezing the 
sample itself. This was done by creating five separate storage-lists for the frozen samples: 
refreeze of the sample, freezing of material from the CLED control agar, freezing of K. 
pneumoniae colonies from the SCAI agar, freezing of E. coli and/or K. pneumoniae colonies 
from the CHROMagar ESBL plate, and freezing of E. coli and/or K. pneumoniae colonies from 
the CHROMagar mSuperCarba plate.  
 
Before cultivation, each sample had to be reactivated in the Analytix system, re-registered with 
the new registration code and entered into the storage list for refreezing of the remaining sample 
material. This had to be done manually for each sample.  
 
The samples were then thawed and 100 µl was cultivated on four different agar plates, each 
described in more details below. The remaining sample material in the E-swab tube was then 
frozen at -70°C in a separate Cryovial 2ml cryotube (Simport) for the prospects of future 
research. The agar plates were incubated at 37°C.  
 
Each sample was examined after ~24 hours incubation. A swipe of the growth on the CLED 
control plate was frozen, using standard freezing broth (see attachment A) for additional 
research purposes in the future. Each sample was therefore registered into the CLED agar 
storage list. Suspicious colonies growing on SCAI, CHROMagar ESBL and/or CHROMagar 
mSuperCarba (more detailed description in chapter 3.2.2 to 3.2.5.) were identified using a 
MALDI Microflex LT mass spectrometer by Bruker Daltonics (the procedure is described in 
details in chapter 3.3). If the result was E. coli or K. pneumoniae, the sample was registered in 
the appropriate storage list, and the isolate was frozen at -70°C using a standard freezing broth 
(see attachment A). When required, the colonies were re-plated on CLED agar for better 
isolation prior to identification or freezing. This procedure was repeated for all the 662 samples 
included in the project. 
 
After completion of the general screening of the fecal samples, all the collected (frozen) strains 
were inoculated on lactose agar, with and without ampicillin (see attachment A) and incubated 
at 37°C for ~24 hours. Each isolate was then subjected to phenotypic antibiotic susceptibility 
testing either by disk diffusion (K. pneumoniae) or by microbroth dilution (ESBL-producing K. 
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pneumoniae/E. coli) (both methods are described in more details in chapter 3.5). DNA extracted 
from the strains accumulated from the ESBL agar was then sent to whole-genome sequencing 
at The Genomics Support Center Tromsø at UiT – The Arctic University of Norway (DNA 
isolation procedure is described in chapter 3.4.1). The sequences were then processed by several 
different bioinformatics tools as described in chapter 3.4.3. Figure 6 shows the overall 
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3.2.2 Cled agar 
Cysteine Lactose Electrolyte Deficient (CLED) agar (see attachment A for details) was used as 
a growth control, meaning if there was no growth on the control agar the sample was discarded. 
This agar was chosen due to its inhibitory effect on the swarming of Proteus sp., which was 
expected to be present in some of the fecal samples [86]. The CLED agar was produced 
according to the manufacturer`s instructions (MAST). 
 
3.2.3 SCAI agar 
Simmons citrate agar with inositol (SCAI) is a 
selective agar for K. pneumoniae and Klebsiella 
oxytoca (see attachment A for details on 
contents and recipe) [87]. Isolating K. 
pneumoniae from fecal samples is challenging 
due to the abundance of E. coli in faeces [87]. K. 
pneumoniae is often represented far less 
numerous compared to E. coli in fecal samples 
[87]. The SCAI agar contains citrate and inositol 
as the only carbon sources, both of which can be 
fermented by K. pneumoniae and K. oxytoca, but 
not by E. coli [87]. The agar also contains bromthymol blue as a pH indicator which means the 
desired Klebsiella sp. colonies can also be differentiated based on the colour of the colonies 
[87]. The fermentation of inositol leads to acid production which lowers the pH and the colour 
changes from blue to yellow [87]. The fermentation of citrate elevates the pH and the colonies 
becomes blue [87]. Figure 7 shows a K. pneumoniae strain growing on a SCAI agar plate. 
Studies have shown the sensitivity of this agar to K. pneumoniae to be 92,5 % [88]. The agar 
was incubated overnight at 37°C and any yellow or blue large colonies were identified using 




Figure 7: K. pneumoniae isolate (Positive 
control strain ATCC 700603) growing on a SCAI 
agar plate. (Photo by L. L. E. Andreassen). 
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3.2.4 CHROMagar ESBL 
CHROMagar ESBL (CHROMagar) is a selective 
and differentiating agar designed to detect ESBL-
producing Gram-negative bacteria (see 
attachment A for details) [89]. The agar contains 
antibiotics favoring ESBL-producing strains, 
while non-ESBL producing strains will be 
inhibited [89]. CHROMagar ESBL also contains 
color indicators which allows for differentiation 
between different species based on color change 
[89]. E. coli will grow on the agar with large 
pink/reddish colonies, while K. pneumoniae will 
grow with dark blue colonies [89]. Because of false positive results caused by bacteria with 
intrinsic AmpC expression, the agar is designed to inhibit AmpC-producing bacteria [89]. The 
agar was produced according to the manufacturer’s (CHROMagar) instructions, and consists 
of a CHROMagar base powder, in addition to a CHROMagar ESBL supplement for selection 
of ESBL producing bacteria. After seeding the samples, the agar plates were incubated for 18-
24 hours in 37°C. The manufacturer specifies the sensitivity of the CHROMagar ESBL to be 
99,2 %, and the specificity to be 89 % [89]. Figure 8 shows a CTX-M-15-producing E. coli 
growing on a CHROMagar ESBL agar plate. 
 
 
3.2.5 CHROMagar mSuperCarba 
CHROMagar mSuperCarba (CHROMagar) is a selective and differentiating agar designed to 
detect carbapenemase-producing Gram-negative bacteria (see attachment A for details on 
contents)  [90]. The agar contains antibiotics favoring strains displaying carbapenemase-
production and is designed to detect Gram-negative bacteria producing a wide selection of 
carbapenemases, including KPC, NDM, VIM, IMP and OXAs [90]. Along with the 
CHROMagar ESBL, this agar also contains color indicators, which allows for differentiation 
between different species based on color change [90]. E. coli will grow on the agar with large 
Figure 8: E. coli isolate (Positive control strain 
EO 499) growing on a CHROMagar ESBL agar 
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pink/reddish colonies, while K. pneumoniae will grow 
with dark blue colonies [90]. The agar was produced 
according to the manufacturer’s (CHROMagar) 
instructions. After seeding the samples, the agar plates 
were incubated for 18-24 hours in 37°C. The 
manufacturer does not specify this agar`s sensitivity or 
specificity [90]. Figure 9 shows a OXA-48 
carbapenemase-producing K. variicola.  
 
 
3.2.6 Other agar plates 
In addition to the four main agar plates included in the screening pipeline, three other agar 
plates were used in this project, lactose agar, lactose agar with 100mg/L ampicillin and Mueller-
Hinton agar (see attachment A for details on contents in each medium). The lactose agar was 
used to seed frozen isolates, as growth control during susceptibility testing and as additional 
seeding media when needed. The lactose agar containing ampicillin was used to seed the frozen 
ESBL-producing isolates from NORM and the isolates from Tromsø-7 suspected of producing 
ESBLs. It was also used as growth control during susceptibility testing on the same isolates. 
Mueller-Hinton agar was used to perform susceptibility testing by agar diffusion. 
 
 
3.2.7 Control strains 
All three of the selective and differentiating agars were produced at the media production unit 
at the Dept. of Microbiology and Infection Control, University Hospital in Tromsø. To ensure 
the media`s quality different control strains with and without b-lactamase genes was used. 
Table 6 lists all the control strains used and specifies the expected result on the different agars 
and also what kind of b-lactamase the positive control strains produce. Some of the control 
strains are commercially available strains (ATCC), while others are obtained from patient 
samples at the Norwegian National Advisory Unit on Detection of Antimicrobial Resistance 
(K-res). 
 
Figure 9: K. variicola isolate (Positive 
control strain 5087 8013) growing on a 
CHROMagar mSuperCarba agar plate. 
(Photo by L. L. E. Andreassen) 
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Table 6: List of control strains for quality control of the different agar plates. 
SCAI	agar	
ATCC	700603	 Klebsiella	pneumoniae	 Pos.	control	 ESBL-	producing	(SHV-18)		
ATCC	25922	 E.	coli	 Neg.	control	 	
50878013	 Klebsiella	variicola	 Pos.	control	 Carbapenemase-producing	
(OXA-48)	
CHROMagar	ESBL	
ATCC	25922	 E.	coli	 Neg.	control	 	
ATCC	29212	 Enterococcus	fecalis	 Neg.	control	 	
	
ATCC	700603	 Klebsiella	pneumoniae	 Pos.	control	 ESBL-producing	(SHV-18)		
EO	499	 E.	coli	 Pos.	control	 ESBL-producing	
(CTX-M-15)	
CHROMagar	mSuperCarba	
50878013	 Klebsiella	variicola	 Pos.	control	 Carbapenemase-producing	
(OXA-48)	
K71-77	 E.	coli	 Pos.	control	 Carbapenemase-producing	
(NDM)	
EO	499	 E.	coli	 Neg.	control	 ESBL-producing	
(CTX-M-15)	
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3.3 Identification of isolates using MALDI TOF 
Cultivated bacteria was identified using the 
MALDI Microflex LT mass spectrometer by 
Bruker Daltonics. Matrix assisted laser 
desorption ionization time of flight mass 
spectrometry (MALDI TOF MS) identifies 
different bacteria based on protein 
composition [91]. A single bacterial colony 
is smeared on a steel target plate , as seen in 
Figure 10, and covered in an energy-
absorbent matrix [91]. The target plate is 
then loaded into the MALDI TOF MS, 
where the sample is ionized by a laser beam [91]. The charged particles are then separated in 
an electrically charged field and proceeds into the “time-of-flight” tube [91]. The time required 
to travel through this tube to the detector in the other end, is proportional to the protein`s size 
[91]. The MALDI TOF produces a spectrum visualizing the intensity of a range of proteins of 
different sizes, called a peptide mass fingerprint (PMF) [91]. This PMF is then compared to 
known PMFs in the database and a probable identification is set with a score describing the 
probability of the match [91]. A report is then produced containing a list of the ten best matches 
for each isolate. 
 
Procedure: 
1. A small portion of a colony was applied to a specific position on the MALDI TOF 
target plate using a wooden toothpick. 
2. The position was then covered with 1µl matrix solution (Bruker Daltonics. See 
attachment A for details).  
3. When the matrix solution was visibly dry, the target plate was inserted into the MALDI 
TOF MS.  
4. Each of the samples on the target plate was registered in the MALDI Biotyper Realtime 
Classification software program, version 3.1. (Bruker Daltonics) and the identification 
process was started. The identification procedure was run with a standard method, 
Figure 10: The MALDI TOF steel target plate with 
isolates applied to specific positions on the plate and 
covered in Matrix solution.                        (Photo by 
L. L. E. Andreassen) 
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MBT_AutoX, and each PMF was compared to the Bruker Daltonics database, MBT 
compass library DB-5989 #1829023 (version v5.0.0.0). 
5. The list with the end results were printed out and each result was manually entered into 
the Analytix LIS program, with designated species and top score. 
 
3.4 Whole-genome sequencing (WGS) 
165 clinical strains of ESBL-producing E. coli and K. pneumoniae, isolated from urine and 
blood cultures through NORM, were sent to GATC Biotech AG in Germany for WGS. The 
company also provided isolation of DNA. The NORM isolates were stored at -70°C upon 
collection in 2014, and was therefore first inoculated on a total of three lactose agar plates, the 
inoculation pattern was extremely dense to yield the amount of material requested by GATC 
Biotech AG. After overnight incubation, pellets were made by suspending the colonies in 1ml 
0.85% NaCl (see attachment A for details) in a 1.5ml Micro-tube (Sarstedt) and then 
centrifuging the tube at 15 000 RPM for 10 minutes using a Microfuge 18 centrifuge (Beckman 
Coulter). This process was then repeated to achieve the goal of a pellet weighing 500mg, which 
was the amount of material recommended by GATC Biotech AG. Once the pelleting process 
for each isolate was done, the Eppendorf tube containing the pellet was again frozen at -70°C. 
When this procedure was completed for all 165 isolates, the Eppendorf tubes were packed in 
small freezing boxes and sent to Germany in a larger box containing freezing elements. 
 
25 strains (2 K. pneumoniae and 23 E. coli) suspected of being ESBL-producers, isolated from 
the fecal samples collected through the Tromsø-7 study were delivered to the Genomics 
Resource Center Tromsø at UiT for WGS. DNA isolation from these strains was done in-house 
as described below. 
 
3.4.1 DNA isolation 
DNA isolation from the ESBL-producing strains from Tromsø-7 was performed using the 
NucliSens EasyMAG system (BioMerieux). This system is based on the binding of free DNA 
to magnetic silica beads [92]. The bacterial cells are first lysed to gain access to the bacterial 
DNA [92]. During the automatic isolation process in the EasyMag instrument, bacterial DNA 
is bound to the magnetic silica beads and the beads are then immobilized by a magnetic device 
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[92]. Several washing steps are performed to purify the DNA in each sample [92]. After the last 
washing step, the bound DNA is released from the beads by adding an elution buffer. The 
magnetic device then removes the silica beads from the eluate [92].  
 
Procedure: 
1. Pellets of each bacterial isolate was made by making a 4 McF suspension in 0.85% NaCl 
(see Attachment A for details).  
2. 1.4 ml of the suspensions were transferred into 1.5 ml Eppendorf-tubes (Eppendorf).  
3. The tubes were then centrifuged at 9000 RPM for two minutes, using	a	Microfuge	18	
centrifuge	(Beckman	Coulter) and the supernatant was discarded. The procedure was 
repeated twice to increase the volume of pelleted cells.  
4. The bacterial pellets were then suspended in 200 µl lysozyme solution (Sigma-Aldrich) 
containing 50mg/mL of lysozyme added to NucliSens®easyMAG Lysis Buffer 
(Biomerieux), and the solution was incubated for 30-40 minutes at 37°C. The lysozyme 
(Sigma-Aldrich) is an enzyme, extracted from chicken egg white, that breaks down 
bacterial cell walls [93].  
5. After incubation, 20 µl (20 mg/ml) Proteinase K PCR Grade (Roche) was added and the 
tubes were incubated on a heat block (Grant) at 55°C. Proteinase K is an enzyme used 
to inactivate endogenous nucleases during DNA isolation [94].  
6. 800 µl NucliSens®easyMAG Extraction buffer 3 (Biomerieux) was added to individual 
wells in the sample cassettes belonging to the easyMAG system,  
7. 200 µl of the lysates was then added to each well.  
8. The sample cassettes were placed in the instrument and a lysisbuffer was added by the 
instrument according to a standardized procedure.  
9. The automated isolation process was then started. The instrument was set on a program 
for extracting DNA from whole blood.  
10. A solution containing the silica beads (Biomerieux) for binding of DNA was added 
after 10 minutes.  
11. When the instrument had finished, after about an hour, the eluates were transferred into 
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After the isolation process, the purity of DNA was measured along with the amount of DNA in 
each sample. 
 
The purity of the extracted material was determined using Nanodrop (Thermo Scientific). 
Nanodrop is based on spectrophotometry, where ultraviolet light is passed through the sample 
[95]. DNA and RNA will absorb a fixed amount of this light, while the rest passes through to a 
detector [95]. The detector records the amount of light absorbed by the sample, which is directly 
correlated to the amount of DNA and RNA in the sample [95]. A wavelength of 260 nm is used 
to determine the amount of DNA in the sample, while the ratio between measurements at 260 
nm and 280 nm is used to determine the purity of DNA in the sample compared to the amount 
of protein contaminants, as proteins absorbs light at 280 nm [95]. Additionally, the ratio 
between 260/230 nm is also registered, to assess possible contamination of other organic 
compounds [95]. Recommended criteria set for purity ratios are generally for 260/280 nm: 1.8 
– 2.0, and for 260/230: 2.0 – 2.2 [95]. 
 
The amount of DNA present was determined using a Qubit fluorometer (Thermo Fisher 
Scientific). This method is based on target-specific fluorescence, which is achieved by adding 
a fluorophore to the eluates that will bind exclusively to the DNA in the sample [96]. The 
intensity of the fluorescent signal is therefore proportional to the amount of DNA in the sample 
[96]. The exact amount of DNA is determined using a set of standards of known concentration 
to create a standard curve, from which the sample is interpreted [96]. For this project, the Qubit 
dsDNA HS Assay Kit (Thermo Fisher Scientific) was used, the kit contains assay reagent 
(fluorophore) and DNA standards [96]. HS means “high sensitivity” and the kit is designed to 
be used on sample concentrations from 10pg/µl to 100ng/µl [96]. The recommended criteria 
for satisfactory amount of DNA was > 20µg/µl [96]. 
 
3.4.2 Illumina sequencing 
All the isolated strains were sequenced using Illumina Next Generation Sequencing (NGS) 
technology [97]. This technology is based on sequencing by synthesis, meaning the different 
nucleotides is detected as they are built into the synthesized chain [97]. This is achieved by 
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This process begins with the fragmentation of DNA in the sample and the addition of different 
adapter sequences that binds to the ends of the DNA fragments [97]. These adapters consist of 
different primers, unique barcodes and specific fragments complementary to oligos in the flow 
cell in the Illumina sequencer [97]. The fragmented DNA is then entered into this flow cell with 
the complementary adapters (oligos) attached to the surface, and one end of the fragments will 
then bind to these immobilized adapters [97]. A new strand is then synthesised by a polymerase 
and the original strand is then washed away. The adapter on the other end of each of the 
synthesized fragments will then bind to another (different) complementary adaptor on the flow 
cell, forming a bridge [97]. The different strains in the flow cell are then synthesized and one 
end of the bridge is then detached, forming two copies of the original fragment [97]. This 
process is done repeatedly to create clusters of synthesized fragments on the surface of the 
flowcell [97]. When the amplification is done, the reverse strands of all the fragments are 
cleaved off, this leaves only the forward strands left on the flowcell [97]. The actual sequencing 
of the fragments now starts by adding single nucleotides to create a new copy of all the 
fragments [97]. The nucleotides are labelled with a fluorescent dye and the emitted light is 
detected by a camera as the synthesis progresses, this process is called sequencing by synthesis 
[97]. After all the forward strands have been synthesized and read, the new copy of the strands 
are discarded and the process starts again, only this time the forward strains are cleaved off and 
discarded [97]. The result is millions of reads from each sample [97]. 
 
3.4.3 Bioinformatic tools 
The sequences provided by Illumina came in the form of a large number of overlapping paired-
end sequence reads [98]. To obtain contiguous sequences, assembly of these overlapping reads 
is required [98]. Once the reads are assembled into contigs, the data can be analysed, for 
instance by comparing the contigs to known sequences and/or to other obtained sequences. 
Figure 11 gives an overview of the different bioinformatics tools included in the bioinformatics 
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Figure 11: Overview of the different bioinformatics tools involved in the bioinformatics pipeline for assembly 
construction and data analysis. 
 
3.4.3.1 Trimmomatic 
Trimmomatic is a very useful tool that is optimized for trimming the Illumina reads, for 
example to get rid of adapter sequences added during the sequencing process and poor quality 
bases that can be problematic during the assembly of the reads [99]. The forward and reverse 
reads from the WGS were stored in separate files. It was therefore important to use a pre-
processing tool that was pair-aware, so that the positioning (connection) of the reads belonging 
to the same fragment was maintained for later assembly [99]. Trimmomatic was designed to 
meet the need for an effective, pair-aware preprocessing tool for Illumina data especially. The 
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main processing steps within the program are identification and removal of adapter sequences, 
and quality filtering [99].  
 
The following command was used to run Trimmomatic: 
“java -jar Trimmomatic-0.36/trimmomatic-0.36.jar PE 
P19_71_lib119254_4654_5_1.fastq.gz 
P19_71_lib119254_4654_5_2.fastq.gz pair_R1.fastq.gz 
unpair_R1.fastq.gz pair_R2.fastq.gz unpair_R2.fastq.gz 
ILLUMINACLIP:Trimmomatic-0.36/adapters/TruSeq3-
PE.fa:2:30:10 LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 
MINLEN:36” 
 
“LEADING:3” and “TRAILING:3” indicate the minimum quality required to keep a base in 
the start and end of the read, respectively. 
“SLIDINGWINDOW:4:15” is the specified threshold for the quality of the read. “4” specifies 
the window size (number of bases to average across), while “15” is the average quality 
threshold.  
“MINLEN:36” is the minimum length required for the reads, any reads under this length will 
be discarded.  
 
3.4.3.2 SPAdes 
To assemble the reads into contiguous sequences (contigs), the assembly algorithm “St. 
Petersburg genome assembler” (SPAdes) was used. The SPAdes algorithm is based on using a 
de Bruijn graph to construct contigs [100]. The short reads are converted into K-mers which 
are used to build a de Brujin graph [98]. K-mers illustrate all the possible substrings (of for 
example four bases – 4-mers) of a specific read [98]. The distance between these K-mers are 
estimated, and the overlapping K-mers are then assembled into contigs [98]. The contigs are 
now stored as fasta files [98]. This assembly approach where the reads are assembled without 
the use of a reference genome is called “De novo” assembly [98].  
 
The following command was used to run SPAdes: 
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 “SPAdes-3.8.0-Linux/bin/spades.py -1 pair_R1.fastq.gz -2 
pair_R2.fastq.gz -s unpair_R1.fastq.gz -s 
unpair_R2.fastq.gz --careful -o assembly” 
 
The “-1” and “-2” refer to the forward and reverse reads, respectively. 
 
3.4.3.3 Quast 
Quality assessment tool for genome assemblies (QUAST) is a very useful tool to evaluate 
assembled genomes. The program generates reports on the quality of the assembled genome 
along with an extensive visualization of these data [101]. Some examples of the assessed 
parameters are the number of contigs in the assembly (the fewer the better), the length of the 
largest contig, the total number of bases in the assembly and the GC content [101]. For this 
project, the quality criteria for the assembly was set to <400 contigs in the assembly, 40x 
coverage, and the GC content and total genome size should not deviate too much from the 
reference genome for the particular species. Another parameter for assembly evaluation is the 
N50 value [101]. To determine this value all the contigs are sorted by size, and the N50 value 
is the size of the median contig, if this is large, there is a likelihood for the rest of the contigs 
being large too [101]. If the N50 value is small, the majority of the contigs are most likely very 
short. These parameters can also be visualized in different plots [101]. 
 
3.4.3.4 Mauve 
Mauve is a tool for aligning two or more genomes with unequal gene content [102]. The 
program is originally designed for comparing genomes for the identification of genome 
rearrangements [103]. In this project, it was used to align the sequenced strains with reference 
genomes as a quality assessment of the assembled genomes. The reference genomes, E. coli 
ATCC 25922 and K. pneumoniae MGH 78578, were downloaded from genbank. The 
assembled genomes from NORM and Tromsø-7 were then compared to the coinciding 
reference genome. If more than 50% of the contigs did not align with the reference genome, the 
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3.4.3.5 Databases 
The assemblies of the sequenced K. pneumoniae and E. coli genomes were submitted to several 
different databases for detection of specific genes. The Centre for Genomic Epidemiology 
(CGE) is situated in Denmark and hosts a series of different genomic databases, such as 
“ResFinder” and “MLST” [104].  
 
In this project ResFinder, version 2.1, was used to identify known acquired antimicrobial 
resistance genes within the sequenced isolates. The ResFinder database contains thousands of 
known acquired resistance genes originating from a wide range of bacterial classes [105]. The 
database is designed to process data from four different sequencing platforms (including 
Illumina), and the data can be pre-assembled, or short reads or complete (or partially complete) 
genomes [105]. The antimicrobial configurations selected for this project was an %ID threshold 
of 90%, selected minimum length of 60%, and the type of reads as “Assembled 
genome/contigs”. 
 
The MLST database was used to determine which sequence type each isolate belonged to. This 
is determined by identifying and comparing nucleotide sequences in certain housekeeping 
genes to make up the sequence type [106]. There are different MLST schemes for different 
bacterial species [106]. In the CGE MLST database, there are two different schemes for E. coli 
[104]. Scheme #1 was chosen for this project, it consists of seven housekeeping genes (adk, 
fumC, gyrB, icd, mdh, purA and recA) located in the E. coli chromosome [107]. Scheme #2 is 
based on the same number of genes, but the genes are different compared to Scheme #1(dinB, 
icdA, pabB, poIB, puP, trpA, trpB, uidA), additionally the number of profiles included in 
Scheme #1 (6875 profiles) was much higher compared to Scheme #2 (823 profiles) [107, 108]. 
The K. pneumoniae scheme also consisted of seven genes (gapA, infB, mdh, pgi, phoE, rpoB 
and tonB), and 2644 profiles were included in this scheme [107]. The selected MLST 
configuration was “Klebsiella pneumoniae” and “Escherichia coli#1”, and the type of reads 
was “Assembled genome/contigs”. 
 
3.4.3.6 Phylogenetic trees 
 
The phylogenetic trees were made from isolates of ESBL-producing E. coli from Tromsø-7 and 
NORM 2014, and ESBL-producing K. pneumoniae from NORM. Multiple sequence alignment 
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was performed on protein level using MAFFT to determine homology of the sequences in each 
population [109]. The MAFFT alignments were then linked and the phylogenetic trees were 
constructed using the program RAxML (Randomized Axelerated Maximum Likelihood) [110]. 
The RAxML command PROTGAMMAAUTO was used to construct a best maximum 
likelihood tree with 100 rapid bootstrap replicates [110]. 
 
3.5 Phenotypic susceptibility testing 
For interpretation of zone diameter and MIC values to the SIR system, clinical breakpoints from 
EUCAST (European Committee on Antimicrobial Susceptibility Testing), version 7.1 
(www.eucast.org) was used. 
 
3.5.1 Agar diffusion 
Agar diffusion is an effective and easy method for determining a bacterium`s susceptibility to 
antimicrobial agents [13]. The method is based on creating an antimicrobial gradient on an agar 
plate and measuring inhibition zones for the different applied antimicrobial agents (for details 
on the specific agents used see table 7) [13]. When applying paper discs containing 
antimicrobial agents to an agar plate already inoculated with a bacterial suspension, the 
antimicrobial agents will diffuse into the agar, creating a concentration gradient [13]. The 
bacteria will then start growing (dividing) on the plate, except in the areas around the discs 
where the antimicrobial concentration is high enough to inhibit growth of this particular 
bacterium [13]. The effect will be inhibition zones with no bacterial growth around the discs. 
The diameter of these zones (mm) are then measured and compared to set breakpoints and 




1. Bacterial colonies were suspended in 0.85 % NaCl (see attachment A for details) to 
create a 0.5 McFarland suspension using a DEN-1McFarland Densitometer (Biosan).  
2. The 0.5 McFarland suspension was inoculated on Mueller-Hinton agar plates (see 
attachment A for details) and different paper discs (Oxoid) containing known 
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concentrations of different antibiotics was placed on the agar plate (for details, see table 
7). The suspension was also inoculated on a lactose agar plate for growth control. 
3. The plate was then incubated for 18-24 hours in 37°C.  
4. The diameter of each inhibition-zone was then registered in Analytix. 
 
Susceptibility testing by agar diffusion was performed for the following antimicrobial agents: 
piperacillin-tazobactam, cefuroxime, cefotaxime, ceftazidime, meropenem, Gentamicin, 
aztreonam, ciprofloxacin and trimethoprim-sulfamethoxazole. The concentration of each disc 
is presented in table 7. 
 
Table 7: Antimicrobial agents (Oxoid) tested by disc diffusion with specific concentrations. 
Antimicrobial agent Disc concentration 
Piperacillin-tazobactam 36 µg (piperacillin 30 µg, tazobactam 6 µg) 
Cefuroxime 30 µg 
Cefotaxime 5 µg 
Ceftazidime 10 µg 
Meropenem 10 µg 
Gentamicin 10 µg 
Aztreonam 30 µg 
Ciprofloxacin 5 µg 
Trimethoprim-sulfamethoxazole 25 µg 
 
Agar diffusion was used for K. pneumoniae isolated from SCAI agar from Tromsø-7 (n=97). 
Previously registered data from susceptibility testing by agar diffusion was also acquired from 
the 2014 NORM collection for both K. pneumoniae (n=1243), ESBL-producing K. pneumoniae 
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3.5.1.1 Combination discs for detection of ESBL-producers 
First indication of the occurrence of ESBL-
production in a random isolate is reduced 
susceptibility to third or fourth generation 
cephalosporins [111]. Parallel to the standard 
susceptibility testing by agar diffusion, a 
phenotypic test for the detection of ESBL-
production was also performed. This test is based 
on the properties of clavulanic acid as a b-
lactamase inhibitor [112]. Figure 12 shows the 
effect of the combination discs on an ESBL-
producing E. coli. This test was performed on 
all the strains from Tromsø-7 isolated from the 




1. A 0.5 McF suspension of the desired bacteria in 0.85% NaCl (see attachment A for 
details) was prepared and some of the suspension was inoculated on a lactose agar plate 
for growth control. 
2. The suspension was evenly inoculated on a Muller-Hinton agar plate (see attachment A 
for details) and two pairs of combination discs were applied. One pair consisted of one 
disc with 30 µg cefotaxime and a complementary disc with cefotaxime (30 µg) 
combined with clavulanic acid (10 µg) The other pair consisted of one disc with 30 µg 
ceftazidime and one with ceftazidime (30 µg) combined with clavulanic acid (10 µg).  
3. The agar plates were incubated over night at 37 °C.  
4. The next day the diameter of inhibition zones were registered. A difference in zone 
diameter between the disc containing the cephalosporins alone and its counterparts 
containing the clavulanic acid of 5 mm or more, was interpreted as positive phenotypic 
ESBL-production in the isolate [112]. 
 
 
Figure 12: Illustration of the effect of the combination 
discs for detection of ESBL producing bacteria. The 
photo depicts an ESBL-producing E. coli isolate. 
(Photo by L. L. E. Andreassen) 
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3.5.2 Microbroth dilution system for antibiotic susceptibility testing 
Susceptibility testing of suspected ESBL producing bacteria from Tromsø-7, (n=25) was 
performed using the Sensititre system (Thermo Scientific). This system comprises of Sensititre 
plates with 96 wells containing a selection of antibiotic agents in different concentrations, 
creating a dilution series. The setup of the two Sensititre plates used (NONAG4 and NONAG5), 




1. A 0,5 McFarland suspension in 0.85% NaCl of the isolate in question was prepared and 
the suspension was also inoculated on a lactose agar plate for growth control. 
2. 10 µl of the suspension was added to a Sensititre Cation adjusted Mueller-Hinton broth 
with TES buffer (Thermo	Fisher	Scientific), and the tube-cap was then replaced with 
a special dosage-cap (Thermo	Fisher	Scientific). 
3. 50 µl of this MH broth was then added to the wells in each Sensititre plates using the 
Sensititre AIM pipetting unit (Thermo	Fisher	Scientific). 
4. A plastic film was added to cover wells and the plates were incubated at 37°C for 18-
24 hours.  
5. After the incubation, each well was examined for growth using the Vizion Digital MIC 
Viewing System (Thermo	 Fisher	 Scientific). The MIC (minimal inhibitory 
concentration) value was determined by the first well in the dilution series without 
visible growth, see figure 13. Each plate also contained a positive-growth control well. 
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Figure 13: Caption of the examination of a Sensititre plate inoculated with an E. coli isolate. Bacterial growth is seen 
as dark areas (red arrow) in the wells (Photo by L. L. E. Andreassen) 
 
Susceptibility testing by broth dilution was performed for the following antibiotic agents: 
amoxicillin-clavulanic acid, piperacillin-tazobactam, cefepime, cefotaxime, cefoxitin, 
ceftazidime, ceftazidime-avibactam, cefuroxime, doripenem, ertapenem, imipenem, 
meropenem, aztreonam, ciprofloxacin, amikacin, gentamycin, tobramycin, tigecycline, colistin, 
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4 Results 
A total of 662 fecal samples were screened for detection of (i) K. pneumoniae irrespective of 
resistance (SCAI agar), (ii) ESBL-producing K. pneumoniae and (iii) ESBL-producing E. coli. 
Only one isolate in each group from each fecal sample with positive growth on the agar plates 
were selected for subsequent analysis. Ninety-seven isolates of K. pneumoniae were obtained 
from cultivation on SCAI agar. From the CHROMagar ESBL plates, 25 isolates were initially 
obtained of which 23 were E. coli and two were K. pneumoniae. No E. coli or K. pneumoniae 
were observed on the CHROMagar mSuperCarba agar. The control strains were cultivated on 
the different agar plates for each new production batch of each of the agars. All the positive 
control strains grew on the respective agar plates as expected, and none of the negative control 
strains were able to grow.  
 
4.1 Results Klebsiella pneumoniae from Tromsø-7 
 
From the 662 fecal samples, 97 K. pneumoniae isolates were acquired from SCAI agar plates, 
resulting in a carriage prevalence of 14.7 %. All the strains were identified as K. pneumoniae 
using MALDI TOF MS. Results of antimicrobial susceptibility testing performed by agar 
diffusion of the 97 K. pneumoniae isolates are presented in figure 14. All isolates were 
susceptible to cefuroxime, cefotaxime, meropenem and aztreonam. For piperacillin-
tazobactam, 85 of the isolates (87.6%) were sensitive, 11 isolates (11%) were intermediate and 
one isolate (1%) was resistant. For ceftazidime, 95 isolates (98%) were sensitive, while one 
isolate (1%) was intermediate and one (1%) was resistant. For gentamicin, 92 isolates (95%) 
were susceptible and five isolates (5%) were intermediate. For ciprofloxacin, 86 isolates (89%) 
were susceptible, while 11 isolates (11%) were intermediate. For trimethoprim-
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Figure 14: Susceptibility profile of K. pneumoniae isolates obtained from Tromsø-7, presented with percentage of 
isolates categorized as sensitive (S), intermediate (I) or resistant (R) for each of the antibiotic agents included in 
the analysis. 
 
To compare the susceptibility profile of K. pneumoniae carriage isolates with clinical K. 
pneumoniae isolates, the susceptibility profiles of the 97 K. pneumoniae strains obtained from 
the Tromsø-7 fecal samples were compared to data for 1243 K. pneumoniae clinical strains 
gathered through NORM 2014. With respect to the NORM strains, 625 were isolated from urine 
samples and 618 were isolated from blood cultures. Data on these strains were obtained from 
the NORM 2014 report [22]. Figure 15 shows a comparison of the Tromsø-7 carriage isolates 
to the NORM 2014 clinical isolates. As the diagram shows, there were only minor differences 
in susceptibility between the clinical strains and the carrier strains for most of the antimicrobial 
agents included in the analysis. However, there is a general trend of higher levels of non-
susceptibility for the tested antimicrobial agents in the clinical isolates compared to the carrier 
strains. The most prevalent difference in susceptibility seems to be for trimethoprim-
sulfamethoxazole, for which 1% of the carrier isolates were resistant, while over 10% of the 
clinical strains showed reduced susceptibility. Moreover, for cefuroxime (CXM) and 
cefotaxime (CTX), all the carrier strains were susceptible, while 8% and 3% of the clinical 
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piperacillin-tazobactam, ciprofloxacin and gentamicin, where there is a higher level of non-
susceptibility in the carriage strains. However, a higher proportion of the clinical strains were 
fully resistant to these agents while the carrier strains were categorized as intermediate. All 




Figure 15: Susceptibility profiles of K. pneumoniae carriage isolates obtained from Tromsø-7 compared to the 
susceptibility profiles of clinical K. pneumoniae isolates from the 2014 NORM collection. Data obtained from NORM 
are divided in strains isolated from urine, and strains isolated from blood cultures (BLC). The susceptibility profiles 
are all presented with percentage of isolates categorized as sensitive (S), intermediate (I) or resistant (R) for each 
of the antibiotic agents included in the analysis; piperacillin-tazobactam (TZP), cefuroxime (CXM), cefotaxime 
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4.2 Results ESBL-producing isolates from Tromsø-7 
 
From the 662 fecal samples, 25 isolates suspected of being ESBL-producers were obtained 
using the CHROMagar ESBL agar. Using MALDI TOF, 23 of these isolates were identified as 
E. coli and two isolates as K. pneumoniae. One fecal sample yielded both E. coli and K. 
pneumoniae. 
 
4.2.1 Phenotypic results ESBL-producing isolates from Tromsø-7 
 
Susceptibility testing of the suspected ESBL-producing isolates from Tromsø-7 was performed 
by broth microdilution. Figure 16 shows the phenotypic susceptibility profile of the E. coli 
isolates, and figure 17 shows the phenotypic susceptibility profile of the K. pneumoniae 
isolates. 
 
As shown in figure 16, all 23 of the E. coli isolates were susceptible to ceftazidime-avibactam, 
doripenem, ertapenem, imipenem, meropenem, amikacin, colistin, forsfomycin and tigecycline.  
For amoxicillin-clavulanic acid, 10 of the isolates (43%) were susceptible, while 13 (57%) were 
resistant. For piperacillin-tazobactam, 21 isolates (91%) were sensitive, one (4%) was 
intermediate and one (4%) was resistant. For cefepime, three isolates (13%) were susceptible, 
12 isolates (52%) were intermediate, and eight isolates (35%) were resistant. For cefotaxime, 
two isolates (9%) were sensitive, two isolates (9%) were intermediate, and 19 isolates (83%) 
were resistant. For cefoxitin, 14 isolates (61%) were sensitive (using the screening breakpoint) 
and nine isolates (39%) were resistant. For ceftazidime, nine isolates (39%) were sensitive, six 
isolates (26%) were intermediate and eight isolates (35%) were resistant. For cefuroxime, two 
isolates (9%) were sensitive, while 21 isolates (91%) were resistant. For aztreonam, four 
isolates (17%) were sensitive, six isolates (26%) were intermediate and 13 isolates (57%) were 
resistant. For ciprofloxacin, 12 isolates (52%) were susceptible, two isolates (9%) were 
intermediate and nine isolates (39%) were resistant. For gentamycin, 15 isolates (65%) were 
sensitive, while eight isolates (35%) were resistant. For tobramycin, 15 isolates (65%) were 
susceptible, two isolates (9%) were intermediate and six isolates (26%) were resistant. For 
nitrofurantoin, 22 isolates (96%) were susceptible, while one isolate (4%) was resistant. For 
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Figure 16: Susceptibility profile of suspected ESBL-producing E. coli isolates obtained from Tromsø-7, presented 
with percentage of isolates categorized as sensitive (S), intermediate (I) or resistant (R) for each of the antibiotic 
agents included in the analysis. 
 
As shown in figure 17, both K. pneumoniae isolates were susceptible to cefepime, ceftazidime-
avibactam, meropenem, imipenem, ertapenem, doripenem, gentamicin, tobramycin, amikacin, 
colistin and fosfomycin. Both isolates were resistant to cefuroxime. Further, one of the isolates 
(50934266) was also susceptible to cefoxitin, cefotaxime, ceftazidime, aztreonam, 
ciprofloxacin and trimethoprim- sulfamethoxazole, resistant to amoxicillin-clavulanic acid, 
piperacillin-tazobactam and nitrofurantoin, and intermediate for tigecycline. The other isolate 
(50936472) was susceptible to amoxicillin-clavulanic acid, piperacillin-tazobactam, 
nitrofurantoin and tigecycline, and resistant to ceftazidime, cefotaxime, aztreonam, 



































Figure 17: Susceptibility profile of ESBL producing K. pneumoniae isolates obtained from Tromsø-7, presented with 
percentage of isolates categorized as sensitive (S), intermediate (I) or resistant (R) for each of the antibiotic agents 
included in the analysis. 
 
Parallel to the phenotypic susceptibility testing, each isolate was phenotypically tested for 
ESBL-production by a combination disc test. Two E. coli isolates (50929671 and 50929669) 
and one K. pneumoniae isolate (50934266) gave a ratio below the set parameters, resulting in 
a negative test result. One E. coli isolate (50922842) had a very low ratio, just over the set 
parameters. The remaining isolates were phenotypically positive for ESBL-production. 
 
4.2.2 Genotypic results ESBL-producing isolates from Tromsø-7 
Al isolates from Tromsø-7 suspected of being ESBL-producers based on growth on 
CHROMagar ESBL plates, were subjected to WGS, including the isolates with negative results 
from the phenotypic ESBL-test. Due to a misunderstanding of the labelling of the E. coli and 
the K. pneumoniae isolates originating from the same sample (50936472), the DNA from these 
two isolates were unfortunately mixed during WGS, and the sequences had to be discarded. 
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The genomic data were subsequently processed and used for database searches, to determine 
STs and presence of known AMR-genes. For the ESBL-producing E. coli isolates, these data 
showed in total 13 different STs, along with two isolates with novel sequence types. The 
dispersal of the different STs are presented as a pie chart in figure 18. The dominant sequence 
type was ST131 (32%). The second most dominant sequence type was ST12 (9%). The other 
represented STs were ST10, ST1290, ST2178, ST38, ST448, ST450, ST617, ST648, ST69, 
ST88 and ST93, each represented with one isolate. Two isolates had a novel ST-type not 
previously described. The two isolates that were phenotypically negative were of ST88 and 
ST131, and the isolate with a low-ratio in the phenotypic test were of a novel ST. 
 
 
Figure 18: ST dispersal within ESBL-producing E. coli from Tromsø-7, shown in percentage 
 
The WGS data also revealed different known AMR genes, and especially interesting for this 
project was the ESBL-genes. As shown in figure 19, the dominating ESBL in E. coli isolates 
from Tromsø-7 was CTX-M-15, which was found in nine isolates (47.4%). Closely following 
was CTX-M-14, which was found in seven isolates (36.8%). CTX-M-8 and CTX-M-27 were 
also present in one (5.3%) and two (10.5%) isolates, respectively. No other ESBL-genes were 
found in this population, and no isolate carried more than one ESBL-gene. Three isolates had 
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phenotypically ESBL negative (50929671 and 50929669) as well as the isolate with a low ratio 
in the phenotypic test (50922842).  
 
 
Figure 19: The dispersal of ESBL variants found in E. coli isolates from Tromsø-7, shown in percentages. 
 
The isolates were also analysed with respect to the presence of other selected AMR 
determinants, including plasmid-mediated AmpC genes, plasmid-mediated quinolone 
resistance genes, 16S rRNA methylases and carbapenemases. 
 
Three of the E. coli isolates, carried the aminoglycoside acetyltransferase-gene, aac(6`)lb-cr, 
which is also shown to affect some fluoroquinolones including ciprofloxacin [51]. All these 
isolates also carried the ESBL-gene for CTX-M-15. No carbapenemase, plasmid-mediated 
AmpC or 16S rRNA methylase genes were identified in any of the E. coli isolates from Tromsø-
7. 
 
As shown in table 8, within the ST131 isolates, there was an evenly dispersal between CTX-
M-14, CTX-M-15 and CTX-M-27, with two enzymes of each within the group. The two isolates 
belonging to ST12, both possessed a CTX-M-14. The rest of the MLSTs seemed to have a 
random dispersal of CTX-M-14, CTX-M-15 and CTX-M-8. The three isolates with aac(6`)lb-
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Table 8: An overview of the different sequence types of the ESBL-producing E. coli isolates from Tromsø-7, and 
the dispersal of selected AMR genes. 
 
 
The genealogy and evolution of these isolates are presented in a phylogenetic tree in figure 20. 
Most of the isolates appeared to be relatively unrelated, with a few exceptions. Two distinct 
clusters of seven isolates in all (outlined in red) were clonally related. All these isolates belong 
to sequence type ST131. Although closely related, six of these isolates harboured three different 
CTX-M ESBLs, while the last isolate did not harbour an ESBL enzyme at all (sample 
50929669). Another cluster of two isolates, outlined in green, were also clonally related. These 
two both belonged to ST12 and they both carried a CTX-M-14 ESBL. 
ESBL-producing E. coli from Tromsø-7 


































ST131 7 2 2 - 2 1 1 with no ESBL gene 
(50929669) 
ST12 2 2 - - -  - 
ST10 1 - 1 - - 1 - 
ST1290 1 1 - - -  - 
ST2178 1 - 1 - -  - 
ST38 1 1 - - -  - 
ST448 1 - 1 - -  - 
ST450 1 1 - - -  - 
ST617 1 - 1 - -  - 
ST648 1 - 1 - - 1 - 
ST69 1 - 1 - -  - 
ST88 1 - - - -  No ESBL gene 
(50929671) 
ST93 1 - - 1 -  - 
Novel 2 - 1 - -  1 with no ESBL gene 
(50922842) 
Total:  7 9 1 2 3  
 
 








Figure 20: Phylogenetic tree with metadata for ESBL-producing E. coli from Tromsø-7. The complete phylogenetic 
tree is seen in the top figure, and a magnified version in the red frame. The columns on the left shows selected 
metadata. The column on the far left is the different sequence types, the middle column depicts the differences in 
CTX-M genes and the column on the right shows which isolates have the aac(6’)-Ib-cr gene. Two clusters are 
outlined in red, these all belong to ST131. The ST12 cluster is outlined in blue. The phylogenetic tree was generated 
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4.2.3 Prevalence of ESBL-carriage in Tromsø-7 
Based on both the phenotypic and genotypic results, three E. coli and one K. pneumoniae isolate 
which initially grew on the CHROMagar ESBL plate, were found to be ESBL-negative. This 
resulted in an overall prevalence of carriage of ESBL-producing E. coli and K. pneumoniae of 
3.2%. For E. coli and K. pneumoniae specifically the prevalence was 3% and 0.2%, 
respectively. 
 
4.3 Results ESBL-producing isolates NORM 2014 
A total of 165 ESBL-producing E. coli and K. pneumoniae isolates were obtained through the 
NORM 2014 collection. Susceptibility testing on these isolates had already been performed 
using agar diffusion and these data were accessed through NORM. In this collection, 126 of the 
isolates were E. coli, 90 of these were isolated from blood cultures, and 36 were isolated from 
urine samples. Thirty-nine of the isolates in were K. pneumoniae, of which 24 were isolated 
from blood cultures and 15 were isolated from urine samples. 
 
4.3.1 Phenotypic data ESBL-producing E. coli NORM 2014 
The E. coli isolates showed limited differences in susceptibility comparing blood cultures and 
urine isolates, as shown in figure 21. The majority (75%) of the isolates were resistant to 
amoxicillin-clavulanic acid. Only a few isolates showed susceptibility to the third generation 
cephalosporins cefotaxime (1%) and ceftazidime (9%). A majority of the isolates were also 
resistant to cefotaxime (98%). One blood culture isolate was intermediate for meropenem (1%), 
the rest were susceptible. For gentamicin 51% of the isolates were resistant, and 83% of the 
isolates were also resistant to ciprofloxacin. For trimethoprim-sulfamethoxazole, 73 % of the 
isolates were resistant. Tigecycline, cefepime and piperacillin-tazobactam was only tested on 
blood culture isolates. All the isolates were susceptible for tigecycline, 95% showed reduced 
susceptibility to cefepime and 69% the isolates were susceptible to piperacillin-tazobactam. 
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Figure 21: Susceptibility profile of ESBL-producing E. coli isolates from blood cultures (BLC) and urine. The data 
was obtained from NORM 2014. The susceptibility profile is presented with percentage of isolates categorized as 
sensitive (S), intermediate (I) or resistant (R) for each of the antibiotic agents included in the analysis; amoxicillin-
clavulanic acid (AMC), cefuroxime (CXM), cefotaxime (CTX), ceftazidime (CAZ), meropenem (MEM), gentamicin 
(GEN), ciprofloxacin (CIP), Trimethoprim-sulfamethoxazole (SXT), tigecycline (TGC), cefepime (FEP) and 
piperacillin-tazobactam (TZP). (*) Data on tigecycline, cefepime and piperacillin-tazobactam was only available for 
blood culture isolates.  
 
4.3.2 Phenotypic data ESBL-producing K. pneumoniae NORM 2014 
The K. pneumoniae isolates showed some differences in susceptibility comparing blood 
cultures and urine samples, as shown in figure 22. The susceptibility profiles will therefore be 
presented both collectively and separately for the antibiotic agents where there were apparent 
differences. In general, the blood culture isolates had a higher degree of resistance. For the 
cephalosporins (cefepime was only tested on blood culture isolates), almost all the isolates were 
resistant (92%-97%). For amoxicillin-clavulanic acid, there were some differences, all the 
blood culture isolates were resistant, while 60% of the urine isolates were resistant. The same 
ratio was seen for piperacillin-tazobactam, 32% of the blood culture isolates, and 20% of the 
urine isolates were resistant. For meropenem, 95% of the isolates were susceptible, while one 
blood culture isolate was intermediate and one urine isolate was resistant. For ciprofloxacin, 
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isolates (60%). The difference between the two sample groups was most prevalent for 
gentamicin, where 75% of the blood culture isolates were resistant, to only 19% of the urine 
isolates. Tigecycline was only tested on blood culture isolates and 75% of the isolates were 
susceptible. From trimethoprim-sulfamethoxazole, the two groups were very similar with 




Figure 22: Susceptibility profile of ESBL-producing K. pneumoniae isolates from blood cultures (BLC) and urine. 
The data was obtained through NORM 2014. The susceptibility profile is presented with percentage of isolates 
categorized as sensitive (S), intermediate (I) or resistant (R) for each of the antibiotic agents included in the analysis; 
amoxicillin-clavulanic acid (AMC), piperacillin-tazobactam (TZP), cefuroxime (CXM), cefepime (FEP), cefotaxime 
(CTX), ceftazidime (CAZ), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), tigecycline (TGC) and 
trimethoprim-sulfamethoxazole (SXT) (*) Tigecycline and cefepime was only available for blood culture isolates. 
 
4.3.3 Genotypic results ESBL-producing isolates from NORM 2014 
All the NORM 2014 isolates were subjected to WGS. One of the isolates (P19_61) was 
characterized as a K. pneumoniae, but when the sequences was obtained, E. coli sequences were 
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4.3.3.1 E. coli 
As illustrated in figure 23, the WGS data showed the NORM E. coli isolates to be strongly 
dominated by ST131, with 56% of the isolates belonging to this sequence type. The second 
most prevalent sequence type was ST405, represented by 8% of the isolates. ST648 and ST38 
both accounted for 5% of the isolates and 3% belonged to ST10. ST617, ST1193, ST372 and 
ST95 each accounted for two percent of the isolates. Two isolates belonged to novel MLSTs 
and the rest of the isolates were distributed among 18 other MLSTs, with one isolate belonging 
to each group.  
 
 
Figure 23: STs in NORM E. coli isolates. Presented in percentages of the total number of isolates. 
 
The distribution of ESBL variants within the NORM E. coli population is illustrated as a pie 
chart in figure 24. The population was greatly dominated by CTX-M-15 which made up 58% 
of the total number of ESBLs. The second most prevalent ESBL was CTX-M-14 with 16%, 
and third was CTX-M-27 with 15.5%. Four isolates carried a CTX-M-1 (3%) and 3 isolates 
carried a CTX-M-55 (2.3%). Two isolates carried a SHV-12, and two isolates had a CTX-M-
24 (1.6%). One isolate had a CTX-M-2, and one isolate harboured a TEM-33-like ESBL 
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Figure 24: Distribution of ESBL variants in E. coli isolates from NORM 2014. Presented in percentages of the total 
number of ESBLs. 
 
With respect to other selected AMR determinants, 55 isolates (43.7%) carried the aac(6`)lb-cr 
gene. Eight isolates had a qnr gene variant, these were in total two qnrB19, two qnrB66-like, 
one qnrB1-like, one qnrB7, one qnrS1 and one qnrVC4. One isolate had a qepA-gene. Two 
isolates carried a 16SrRNA methylase, ArmA. One isolate harboured a plasmid-mediated 
AmpC b-lactamase (CMY-2) and two isolates possessed carbapenemase-genes (blaIMP-26 and 
blaOXA-181), these two isolates had sample number P20_10 and 20_09.  
 
Table 9 shows the correlation between the different sequence types and selected AMR genes. 
Within the ST131 population, CTX-M-15 was the dominating ESBL (55%), followed by CTX-
M-27 (25%). CTX-M-15 was also the dominating ESBL in ST405 (80%), ST648 (57%), ST38 
(71%), ST10 (75%) and both ST617 isolates carried a CTX-M-15. In ST1193, ST372 and ST95, 
CTX-M-15 constitutes 50%, present in one out of two isolates. Within the group “Other STs”, 
CTX-M-15 was also the dominating ESBL with 56%. The isolate with the novel ST, also carried 
a CTX-M-15. One of the ST-131 isolates had a TEM-33 b-lactamase, and the same isolate also 
carried a CTX-M-1. Two isolates had both a CTX-M-14 and a CTX-M-15, both these isolates 
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a CTX-M-15, and belonged to ST95. The isolate carrying an OXA-181 carbapenemase 
(P20_09), was the same isolate that carried the plasmid-mediated AmpC, it also possessed a 
CTX-M-15 and it belonged to sequence type ST410. This was the only isolate of this sequence 
type in the collection. 
 
Table 9: An overview of the different sequence types of the ESBL-producing E. coli isolates from NORM 2014, and 
the dispersal of selected AMR genes. The selected AMR determinants are ESBLs, plasmid-mediated quinolone 
resistance (PMQR) and aminoglycoside resistance (16S rRNA methylases). 
ESBL-producing E. coli NORM 2014 


























































ST131 71 8 39 4 - 2 18 - 1 TEM-33-
like 
30 1 QnrB1-like - - - - 
ST405 10 1 8 - - - - 1 - 9 - - - - 1  
ST648 7 2 4 - 1 - - - - 3 1 QnrB66-like 
1 QnrB19 
- - - - 
ST38 7 4 5 - - - - - - 4 - - - - - 
ST10 4 1 3 - - - - - - 1 - - - 1 - 
ST617 2 - 2 - - - - - - 2 - - - - - 
ST1193 2 - 1 - - - 1 - - 1 - - - - - 
ST372 2 1 1 - - - - - - 1 - - - - - 
ST95 2 - 1 - - - - 1 1 IMP-26 
1 OXA-181 





4 10 -  - 1 1 2 SHV-12 
1 CMY-2 
4 1 QnrB7 
1 QnrB19 
1 QnrB66-like 
1 1  1  
Novel ST 1 - 1 -  - - - - - - - - - - 
Total  21 75 4 1 2 20 3 5 55 6 1 1 1 2 
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The phylogenetic analysis of the ESBL-producing isolates from NORM 2014, resulted in a very 
large phylogenetic tree. The complete tree is presented in figure 25, however, considering the 
size of the tree, it is divided into two parts (A and B) and presented separately in figure 26 and 
27, respectively. As seen in figure 19, part A generally consisted of many different lineages 





Figure 25: Phylogenetic tree with metadata for ESBL-producing E. coli from NORM. The columns on the right shows 
selected metadata. Due to the size of the tree, it is divided into two parts. Part A is the general part of the tree, while 
part B consists of closely clonally related isolates. Part A and B are presented separately in figure 20 and figure 21, 
respectively. The columns on the tight shows selected metadata. The phylogenetic tree was generated based on 
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As seen in figure 26, part A of the phylogenetic tree for the NORM ESBL E. coli, showed four 
clusters consisting of four to ten isolates, apparently originating from the same linage. Cluster 
one consisted of seven isolates belonging to ST648, cluster two also comprised of seven 
isolates, belonging to ST38. Cluster three was the largest, with ten isolates, all belonging to 
ST405, and cluster four comprised of four isolates belonging to ST10. All these clusters showed 
diversity in terms of CTX-M ESBL, sample material and laboratory.  
 
 
Figure 26: Phylogenetic tree with metadata for ESBL-producing E. coli from NORM, part A. Four different clusters 
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As seen in figure 27, part B of the phylogenetic tree for the NORM ESBL E. coli, showed two 
large clusters all originating from one lineage. All the isolates in this part of the phylogenetic 
tree belonged to ST131. The most dominating ESBLs were CTX-M-15 and CTX-M-27. There 
was much diversity both concerning sample material and originating laboratory.  
 
 
Figure 27: Phylogenetic tree with metadata for ESBL-producing E. coli from NORM, part B. All isolates in this part 
of the phylogenetic tree belong to ST131. 
 
 
4.3.3.2 K. pneumoniae 
The WGS data showed the K. pneumoniae isolates from NORM 2014, to be dominated by 
ST307 (23%), as illustrated in figure 28. The second most dominating sequence types were 
ST15 and ST340 (both 8%), followed by ST231 and ST45 (both 5%). There was one novel ST 
in the population, and the rest of the isolates belonged to 18 different sequence types, with one 














Figure 28: STs in NORM K. pneumoniae isolates. Presented in percentages of the total number of isolates. 
 
Figure 29 shows the distribution of ESBLs within the NORM K. pneumoniae population. The 
population was dominated by CTX-M-15 which makes up 50%. The second most prevalent 
ESBL in the population was SHV-28 with 19%. Four different ESBLs were each found in two 
isolates (3%), these were CTX-M-27, SHV-41, SHV-12 and SHV-2-like. Eleven other ESBLs 
were also only found in one isolate each (1.6%), these were CTX-M-14, SHV-2, SHV-36-like, 
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Figure 29: Distribution of ESBLs in K. pneumoniae isolates from NORM 2014. Presented in percentages of the total 
number of ESBLs. 
 
Concerning other selected AMR determinants, 25 isolates (66%) carried the aac(6`)lb-cr gene. 
Twentyone isolates had a variant of qnr-gene, these variants were 17 qnrB66-like, two qnrB1-
like and one qnrB4. One isolates carried a 16SrRNA methylase, armA. None of the K. 
pneumoniae isolates carried carbapenemase-genes. 
 
Table 10 shows the correlation between the different sequence types and AMR genes 
characterized in the K. pneumoniae population. All the isolates belonging to ST307 carried a 
CTX-M-15, an SHV-28, and a aac(6`)lb-cr gene. In addition, seven of these isolates carried a 
qnr-gene. All the isolates belonging to ST340 harboured CTX-M-15, and carried the aac(6`)lb-
cr gene. In addition, one of these isolates also carried blaTEM-33, armA and qnrB66-like. All the 
ST15 isolates carried CTX-M-15 and a aac(6`)lb-cr gene. In addition, two isolates had a SHV-
28, one had SHV-129 and one had a qnrB66-like-gene. Among the ST45 isolates, one carried 
a CTX-M-15, a SHV-27, a aac(6`)lb-cr gene and a qnr-gene (qnrB1-like). The other carried an 
SHV-12. The rest of the isolates represented 18 different STs, and displayed great diversity in 
AMR markers. The most prevalent ESBL among these isolates was CTX-M-15. Eight of these 
isolates had a aac(6`)lb-cr gene, and 11 carried qnr-genes. There was also one isolate of a novel 
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Table 10: An overview of the different sequence types of the ESBL-producing K. pneumoniae isolates from NORM 
2014, and the dispersal of selected AMR genes. The selected AMR determinants are ESBLs, plasmid-mediated 
quinolone resistance (PMQR) and aminoglycoside resistance (16SrRNA methylases). 
ESBL-producing K. pneumoniae NORM 2014 













































ST307 9 - 9 - 9 - - - - 9 7 QnrB66-like   
ST340 3 - 3 - - - - - 1 TEM-33 3 1 QnrB66-like  1 
ST15 3 - 3 - 2 - - - 1 SHV-129 3 1 QnrB66-like   
ST231 2 - 2 - - - - - - 1    
ST45 2 - 1 - - - 1 - 1 SHV-27 1 1 QnrB1-like   
Other ST  
(18 ulike) 











Novel ST 1 - - 1 - 1 - - -     
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The genetic sequences of the K. pneumoniae isolates were used to construct a phylogenetic tree, 
shown in figure 30, to determine their genealogy and evolution. The phylogenetic tree showed 
one large cluster, outlined in red, consisting of nine isolates. All these isolates were from blood 
cultures, they all belonged to ST307 and they all carried the same CTX-M (CTX-M-15) and 
SHV b-lactamase (SHV-28). They came from several different laboratories, but seemed to be 
closely related descending from the same K. pneumoniae strain. The tree also showed a cluster 
of three isolates, outlined in green. These three isolates came from blood cultures, but from 
three different laboratories. They all belonged to ST15, they all had a CTX-M-15 and a 
aac(6`)lb-cr gene, and had ascended from the same strain. The third cluster, outlined in blue, 
were all ST340 and they all had the same CTX-M (CTX-M-15) and a aac(6`)lb-cr gene. Two 
of them came from the same laboratory while the third came from a different one. They also 
seemed to be descendants of the same strain.  
 
One isolate, P20_15, was highly unrelated to the rest of the population. This isolate belonged 
to ST-334 and harboured a SHV-12 ESBL, and in addition possessed an OKP-B-4-like b-
lactamase. This isolate is most likely a K. quasipneumoniae (KpII), because it is unrelated to 










Figure 30: Phylogenetic tree with metadata for ESBL-producing K. pneumoniae from NORM. The complete 
phylogenetic tree is seen in the top figure, and a magnified version in the red frame. The columns on the right shows 
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depicts the different laboratories which initially handled the sample. The third column shows the differences in STs, 
and the rest of the columns show differences in AMR-genes. Three clusters are outlined in red, green and blue. 
The red cluster consists of ST307, the green is ST15 and the blue is ST340. 
 
4.4 Phylogenetic comparison of ESBL-producing E. coli from 
Tromsø-7 and NORM 
 
The sequenced ESBL-producing E. coli isolates from both Tromsø-7 and NORM, were also 
collectively submitted for phylogenetic analysis, resulting in one phylogenetic tree with all the 
isolates represented. The complete tree is presented in figure 31, however, considering the size 
of this combination tree, it is divided into two parts (A and B) and presented separately in figure 
32 and 33. As seen in figure 31, part A generally consisted of many different lineages with a 




Figure 31: Phylogenetic tree with metadata for ESBL-producing E. coli from both clinical (NORM) and carrier 
(Tromsø-7) isolates. The columns on the right shows selected metadata. Due to the size of the tree, it is divided 
into two parts. Part A is the general part of the tree, while part B consists of closely clonally related isolates. Part 
A and B are presented separately in figure 26 and figure 27, respectively. The columns on the right shows 
selected metadata. The phylogenetic tree was generated based on protein coding sequences using RAxML [110]. 
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As seen in figure 32, part A of the joint phylogenetic tree for the ESBL-producing E. coli 
isolates, showed four clusters consisting of isolates with the same sequence types (as seen in 
figure 26 in chapter 4.3.3.1). The carrier isolates from Tromsø-7 is marked by red arrows, and 
as the figure shows, these were mainly distributed along the tree. However, some of the carrier 





Figure 32: Part A of the phylogenetic tree with metadata for ESBL-producing E. coli from both clinical (NORM) and 
carrier (Tromsø-7) isolates. The columns on the right shows selected metadata. The carrier isolates from Tromsø-
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Part B of the joint phylogenetic tree for the ESBL-producing E. coli isolates is presented in 
figure 33 and showed two large clusters, all originating from one lineage (as seen in figure 27 
in chapter 4.3.3.1). This part comprised only of isolates belonging to ST131. The carrier isolates 
from Tromsø-7 is marked by red arrows, and were distributed in the ST131 lineage. 
 
 
Figure 33: Part B of the phylogenetic tree with metadata for ESBL-producing E. coli from both clinical (NORM) and 
carrier (Tromsø-7) isolates. The columns on the right shows selected metadata. The carrier isolates from Tromsø-
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5 Discussion 
This study investigated the prevalence of carriage of ESBL-producing E. coli and K. 
pneumoniae in inhabitants in Tromsø. Further, the phenotypic susceptibility of these isolates 
was investigated, and the population structure was determined using WGS. The WGS data was 
also compared to WGS data of ESBL-producing isolates from the NORM 2014 collection, 
which was also sequenced as part of this project. 
 
The Tromsø-7 fecal samples were also used to determine the prevalence of K. pneumoniae 
carriage irrespective of resistance in inhabitants in Tromsø. Additionally, the phenotypic 
susceptibility profiles for these isolates was determined and compared to phenotypic 
susceptibility profiles from clinical isolates collected through NORM 2014. 
 
5.1 Fecal carriage of K. pneumoniae in Tromsø-7 
A total of 97 K. pneumoniae isolates irrespective of resistance, were found in 662 fecal samples 
from the Tromsø-7 study, resulting in a prevalence of 14.7 %. This carriage prevalence is 
considerably lower than a Chinese study (62%), an American study (23%) and a Korean study 
(21%) [79-81]. However, the carriage rate in the Tromsø-7 population was higher than the 
prevalence in an Australian study (10%) [82]. Some of these differences could be due to 
difference in methodology in the respective studies. The study with the highest prevalence 
(Chinese study) analysed stool samples from the participants, which were inoculated on 
MacConkey agar and a selective medium for K. pneumoniae (the article does not specify which 
selective medium) [79]. The Korean study also analysed stool samples inoculated on 
MacConkey agar, but these samples were also inoculated in an enrichment broth to increase the 
chance of finding K. pneumoniae [80]. The American and the Australian study both analysed 
rectal swabs, which can give a false negative result as the selection of bacteria in the samples 
is likely to be narrower compared to a stool sample [81, 82]. The Australian study however, 
used an enrichment broth in addition to the MacConkey agar, which will increase the chances 
of finding any K. pneumoniae represented in low numbers in the samples [82]. The fecal 
samples from Tromsø-7 were not inoculated in enrichment broth, so there is likely a false 
negative rate. In addition, the investigation of bacterial growth on the SCAI agar plates was 
challenging as bacterial colonies of other species was often represented in great numbers, which 
could repress the growth of K. pneumoniae. In addition, the Tromsø-7 samples were frozen for 
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a considerably amount of time before inoculation, although adding glycerol to the fecal samples 
prior to freezing, this may have led to a loss of bacterial diversity on the agar plates, and possibly 
false negative results. The Australian study also found a higher prevalence of carriage in the 
previously hospitalized patients (19%) compared to the community associated group of 
patients, this shows the carriage of K. pneumoniae is likely to increase in hospitalized patients, 
and may account for the higher carrier rates in the American study [82]. 
 
A majority of the K. pneumoniae isolates were susceptible to all antimicrobial agents included 
in the analysis. There were limited differences in susceptibility between carrier isolates and 
clinical isolates, however the clinical isolates showed higher levels of non-susceptibility for the 
tested antimicrobial agents compared to the carrier strains. This could indicate that the clinical 
strains have more AMR markers than the carrier strains. The clinical strains were isolated from 
patients suffering from urinary tract infections and blood culture infections, and it is likely a 
large portion of these patients have undergone some sort of antimicrobial treatment, which in 
turn may have selected for more resistant strains of K. pneumoniae. However, to accurately 
compare these populations, more studies are needed. WGS data would give a more extensive 
base for comparison of these populations.  
 
5.2 Fecal carriage of ESBL-producing E. coli and K. pneumoniae 
in Tromsø-7 
 
Initially 25 isolates suspected of being ESBL-producers were found in the 662 fecal samples 
analysed. However, three E. coli and one K. pneumoniae isolate that grew on the CHROMagar 
ESBL agar (16%), were phenotypically and genotypically ESBL-negative. This was to be 
expected considering the manufacturer of the CHROMagar ESBL agar reports a sensitivity of 
99.2% [89]. A sensitivity this high will inevitably lead to some false positive results, and the 
specificity is consequently reported to be 89% [89]. The number of ESBL-producing isolates 
therefore had to be adjusted to 21 isolates, after the results of the phenotypic analysis and whole 
genome sequencing were obtained. This resulted in a prevalence of 3.2%. This prevalence is 
slightly lower compared to a similar Norwegian study by Ulstad et al. from 2016, which showed 
a carriage rate of 4.9% [74]. In this study, rectal swabs were inoculated on a different selective 
agar (MacConkey agar plates supplemented with either cefotaxime, ceftazidime or 
ciprofloxacin) compared to the Tromsø-7 study [74]. Additionally, a MacConkey broth 
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supplemented with cefotaxime was used, which gives an advantage in detecting ESBL-
producing isolates in samples with a low number of bacteria [74]. The difference in carriage 
rates between this study and Tromsø-7 may have been caused by the difference in screening 
media, or as previously discussed, the freezing process of the Tromsø-7 samples, may have led 
to a lower carriage rate. It is also possible that the difference in prevalence is simply a reflection 
of different communities in different regions of the country. The Tromsø-7 study only included 
inhabitants in and around Tromsø, while the Ulstad et al. study was limited to inhabitants in the 
eastern part of Norway [74]. There is also an age difference in the populations between the 
studies. The study by  Ulstad et al. inlcuded participants from 18 to 84 years, while in Tromsø-
7 all partcicipants were over 40 years old [74]. Similar community carriage rates have been 
found through studies in both France and Sweden. A Swedish study by Ny et al. from 2016, 
showed a prevalence of E. coli ESBL-carriage of 4.7%. This prevalence was based on screening 
of community fecal samples using a locally manufactured agar (CHROMoriental-agar with 
cefpodoxime). The French study, by Nicolas-Chanoine et al. showed a prevalence of 4.9% [75]. 
However, this is an older study from 2012, and it concluded with a 10-fold increase in 
prevalence from 2006-2011, so it is likely the prevalence in France today is higher [75]. Another 
Norwegian study from 2012, was based on screening of pregnant women in the south of 
Norway, and found a prevalence of 2.9%, which is in concordance with the Tromsø-7 study 
[72]. However, this study is also several years old, and considering the trends in other countries 
this prevalence is likely to be higher today [75, 78]. Another Norwegian study by Jørgensen et 
al., investigated the ESBL carriage rate in patients with gastroenteritis, and found a 
considerably higher prevalence of 15.8% [73]. Many of these patients had been travelling, and 
there was a correlation between carriage rate of ESBL and travel to Asia, and especially India 
[73]. The study showed the ESBL carriage rate among travellers to India (32 travellers), was 
56.3%, which most likely accounts for the high overall carriage rate in this study [73]. In 
Tromsø-7 all participants have responded to a questionnaire including questions about travel. 
Our future aim is to link our data with the metadata from Tromsø-7 to identify possible risk 
factors for ESBL-carriage. Compared to other world regions, Norway has a very low prevalence 
of ESBL-producing E. coli and K. pneumoniae [19]. As mentioned in the introduction, studies 
show some countries in Asia to have a prevalence of ESBL-producing Enterobacteriaceae of 
over 50%, this was however also in older studies (2008-2010), so there is a high possibility this 
carriage rate is much higher at the present moment [78]. 
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5.3 Comparison of ESBL E. coli population structure in Tromsø-
7 and NORM 2014 
 
Results from the genotypic analysis, showed the ESBL-producing E. coli isolates from Tromsø-
7 to be a very diverse group, belonging to many different sequence types, although clearly 
dominated by ST131 (32%). As mentioned in the introduction, this sequence type is highly 
associated with outbreaks and is known to have a very efficient dispersal world-wide [55]. 
Other ESBL carriage studies also support this observation, in a Dutch study, Reuland et al. 
found ST131 to be dominating (15.9%) in the ESBL-producing E. coli carriage isolates [77]. 
Several of the other similar studies discussed in the previous chapter, did not investigate MLSTs 
among the isolated ESBL strains. The other 12 STs identified were only represented by one or 
two isolates and appears as random clones in the population. However, the small number of 
isolates included in the analysis, makes it difficult to make any clear assumptions regarding the 
population structure of ESBL-producing E. coli in the population of Tromsø. However, the 
identification of the ST131 clone is worrying.  
 
Results from the genotypic analysis, showed less diversity within the NORM E. coli isolates, 
compared to the E. coli isolates from Tromsø-7. Although 28 different sequence types were 
represented within the population, it was clearly dominated by ST131, with 56% of the isolates 
belonging to this group. Studies have shown ST131 to have extensive pathogenic potential as 
numerous virulence markers have been investigated, among these are studies of this ST`s ability 
to establish colonization the intestines, and maintain this colonization over time [55]. Vimont 
et al. proved that ST131 outcompeted non-ST131 commensal strains in mice [115]. 
Dautzenberg et al. investigated the pathogenic potential of ST131, and found that it is 3.2 times 
more pathogenic compared to non-ST131 [116]. Considering these isolates came from clinical 
samples, it was expected to find a majority of the isolates belonging to this well known, highly 
virulent sequence type. The prevalence of ST131 among the NORM ESBL-producing E. coli 
is higher compared to previous Scandinavian studies. A similar study from Denmark in 2013 
showed a 38% prevalence of ST131 among ESBL-producing E. coli in clinical isolates [117]. 
Another Norwegian study from 2009, showed 20% of the clinical ESBL-producing E. coli 
isolates included in the study was ST131 [118]. A Swedish study from 2013, investigated 
clinical ESBL-producing E. coli from 2007-2011, and found 34-38% of the isolates belonged 
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to ST131 [119]. This difference in prevalence of ST131 among clinical strains, most likely 
depict the dissemination success of this clonal group over the years, as described in other parts 
of the world [55]. The high prevalence of ST131 among both the Tromsø-7 and the NORM 
ESBL-producing E. coli, suggests this clonal line has established itself as the dominating ST in 
both clinical and carrier ESBL isolates. This illustrates studies done on this sequence type`s 
advances in the competition for habitats, especially in terms of its ability to colonize, and its 
extensive repertoire of resistance genes [55, 116].  
 
One of the Tromsø-7 E. coli isolates belonging to ST131 (50929669), did not produce an ESBL. 
This was the only representative of ST131 from both collections which did not have an ESBL-
gene. Considering ST131 is closely associated with several CTX-M ESBLs, this is a divergent 
observation. It is possible this isolate initially harboured an ESBL, but that it was lost during 
re-plating and/or freezing of the isolated strain.  
 
The second most prevalent sequence type among the NORM ESBL isolates was ST405 (8%). 
This sequence type has previously been described in clinical isolates in different parts of the 
world, and often carrying a NDM carbapenemase [57, 75]. This sequence type was not found 
in any of the isolates from Tromsø-7, suggesting it has not disseminated in the community with 
the same success as ST131. However, the ESBL-producing E. coli from Tromsø-7 is a very 
small population compared to the NORM collection, so it is difficult to draw any definite 
conclusions regarding the less represented sequence types present in the population.  
 
When it comes to AMR genes in the Tromsø-7 ESBL-producing E. coli isolates, CTX-M 
enzymes were clearly dominating, and among these, CTX-M-15 was the most profuse (47%), 
followed by CTX-M-14 (36.8%). Linking the different STs and the dispersal of ESBL-genes, 
it is apparent isolates belonging to ST-131 is not dominated by a single ESBL, but rather three 
different ESBLs (CTX-M-14, CTX-M-15 and CTX-M-27), evenly spread among the isolates 
(29% of each). Within the NORM collection, CTX-M-15 is the dominating ESBL, carried by 
58% of the E. coli strains. CTX-M-14 was the second most prevalent ESBL in the NORM 
collection followed by CTX-M-27, but the prevalence rate (~16%) was lower compared to 
CTX-M-15. CTX-M-15 was also the dominating ESBL found among the ST131 E. coli, with 
a prevalence of 55%. From other studies it is well known ST-131 is highly associated with 
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especially CTX-M-15, but also CTX-M-14 and CTX-M-27 [55]. Considering ST131 is the 
dominating sequence type among both E. coli populations, it is therefore to be expected these 
three ESBLs is well represented in the populations. Among the ST405 from the NORM 
collection, CTX-M-15 was also the dominating ESBL, in concordance with other studies [57, 
75]. No NDM carbapenemase was found among the ST405 isolates.  
 
In addition, two of the NORM E. coli isolates possessed the genes for carbapenemases (OXA-
181 and IMP-26), however, these two isolates did not display phenotypic resistance to 
carbapenems. This can be explained by studies showing that the presence of a carbapenemase 
do not result in phenotypic carbapenem-resistance according to clinical breakpoints unless there 
are additional AMR markers present, like mutations causing decreased permeability of the cell 
membrane [23]. In addition, one of the NORM E. coli isolates (P21_14) was phenotypically 
intermediate to meropenem, but did not produce a carbapenemase, only a CTX-M-15. This 
reduced susceptibility for meropenem could be caused by other AMR mechanisms, like 
mutation in PBP or downregulation of porins, both mechanisms which have been described in 
E. coli [17].  
 
Three of the E. coli isolates carried a gene for aminoglycoside and fluoroquinolone resistance, 
aac(6`)lb-cr, encoding an acetyltransferase. All three isolates also carried a blaCTX-M-15, which 
can suggest co-localisation on the same plasmid, but this remains to be determined. All three 
of these isolates were phenotypically resistant to gentamicin and tobramycin, and two were 
resistant to ciprofloxacin, while the third was susceptible. There were no carbapenemase-genes 
present in any of the E. coli isolates from Tromsø-7, which is supported by the lack of 
phenotypic resistance for carbapenems within the population and that no isolates were found 
on CHROMagar mSuperCarba agar plates.  
 
Several plasmid-mediated quinolone resistance genes were found in both E. coli populations. 
The most prevalent of these genes was the aac(6`)lb-cr, encoding a fluoroquinolone modifying 
acetyltransferase, which gives reduced susceptibility to both quinolones and aminoglycosides. 
This gene was present in 44% of the NORM E. coli isolates, and in 13% of the Tromsø-7 
isolates. All these isolates also carried one or more ESBL-genes, most prevalent was the 
combination of aac(6`)lb-cr and CTX-M-15, which again was most prevalent in ST131. This 
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co-resistance is supported by studies showing ESBL-production combined with 
fluoroquinolone-resistance is common in this sequence type [55]. No other PMQR genes were 
identified in the Tromsø-7 isolates, but in the NORM isolates, eight qnr-genes were found. I 
addition, a qepA-gene, encoding a fluoroquinolone efflux-pump, was found in one of the E. coli 
isolates, and the aminoglycoside resistance gene armA was also found in two of the NORM 
isolates. These findings show there is less co-resistance among the carrier strains, compared to 
the clinical isolates. The clinical isolates are more likely to have been subjected to selective 
pressure from antimicrobial agents, which can explain this phenomenon. The study did not 
investigate for the presence of chromosomal mutations in gyrA and parC which is the most 
common mechanism of fluoroquinolone resistance [120]. 
 
The phylogenetic tree for the E. coli isolates from Tromsø-7, shows most of the isolates are not 
closely related, but there are also two clusters containing seven isolates in all which are clonally 
related. These isolates represent the entire group of sequence type ST-131 within this 
population. This indicates these isolates all originates from one specific strain that has 
established itself in the community. As mentioned above, even though these isolates are closely 
related, six of them produce three different ESBLs, CTX-M-14, CTX-M-15 and CTX-M-27. 
There is also a small cluster consisting of two isolates, 50932514 and 50937543, which both 
belong to sequence type ST-12, and produces a CTX-M-14. 
 
The phylogenetic tree for the NORM E. coli isolates also shows four minor clusters of related 
strains belonging to sequence types ST648, ST38, ST405 and ST10. However, the isolates 
belonging to each cluster, come from different laboratories and produce different CTX-M 
ESBLs, so there is no apparent pattern except the clonal relation. The most interesting element 
of the NORM phylogenetic tree, however, is the two massive clusters of ST131 isolates. As 
seen with the Tromsø-7 isolates, these two clusters represent the entire population of ST131 
within the NORM isolates. This suggests, as with the Tromsø-7 E. coli, these isolates all share 
a common ancestor. Most likely an ST131 strain has been introduced in Norway and spread 
throughout the community, and has now become the most dominating ESBL-producing clone 
in Norway. The combination of these two phylogenetic trees (Tromsø-7 and NORM) show the 
ST131 carrier isolates are also clonally related to the clinical strains, showing there is no 
fundamental difference between the ST131 population from clinical samples and carrier strains. 
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To more accurately determine the connection of these two populations, an analysis of plasmids 
carried by the different isolates should be performed. Due to time-limitations this analysis 
unfortunately has not been done within the framework of this project.  
 
5.4 ESBL K. pneumoniae population structure in NORM 2014 
 
The population structure of the NORM K. pneumoniae isolates, is highly diverse, representing 
24 sequence types distributed in 35 isolates. The most prevalent sequence type within the K. 
pneumoniae population was ST307 (23%), this sequence type is highly associated with CTX-
M-15 [70], which was found in all the NORM isolates as well. ST307 has in recent years 
emerged in several different countries, and is considered a rising threat, with special emphasis 
on KPC-producing strains. The sequence type was first defined in 2008, and has since been 
identified in high numbers in several countries (Italy, Pakistan, Morocco, Korea and Japan), 
both associated with clinical outbreaks and carriage strains [121]. A surveillance study in Italy 
in 2014 revealed that 28% of KPC-producing isolates belonged to ST307, which is very close 
to the prevalence of ST307 in the NORM K. pneumoniae population [121]. Fortunately, none 
of the NORM ST307 isolates carried a KPC-gene. ST307 was also found to possess traits that 
might give these strains advantages in a hospital environment, including the production of 
capsules, as well as harbouring AMR determinants [121]. This is a probable explanation of the 
dominance of this sequence type in the NORM collection. As there are no ESBL-producing K. 
pneumoniae carrier strains available for comparison, the prevalence rate of this sequence type 
among carrier isolates is unknown. The second most prevalent sequence types were ST15 and 
ST340, although in much lower numbers (8%). ST340 is also associated with CTX-M-15 [71], 
and all three NORM isolates did indeed produce a CTX-M-15, along with all three ST15 
isolates. Both ST340 and ST15 have also been associated with KPC and NDM-
carbapenemases, and especially ST15 have been associated with outbreaks of carbapenemase-
producing K. pneumoniae [122]. No carbapenemase gene was found in the K. pneumoniae 
isolates, although two isolates phenotypically showed reduced susceptibility to meropenem.  
Both isolates harboured CTX-M-15, but no carbapenemase was identified. The reduced 
susceptibility to meropenem displayed by these isolates is most likely caused by another AMR 
mechanism. As an example, the loss of two major porins (OmpK35 and OmpK36) have been 
known to cause carbapenem resistance in isolates of K. pneumoniae [123].  
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Several plasmid-mediated quinolone resistance genes were found in the K. pneumoniae 
populations. Like the NORM E. coli population, the most prevalent of these genes was 
aac(6`)lb-cr, present in 66% of the isolates. This was reflected in the phenotypic susceptibility 
profiles seen for gentamicin, where about 70% of the K. pneumoniae (BLC) were resistant. In 
addition, one isolate carried an aminoglycoside resistance gene (armA). 
 
The second most dominating PMQR-genes in the population were qnr-genes, of which five 
different variants were identified. Combined, these genes show that the majority of the isolates 
possessed some sort of PMQR gene, which is reflected in the high rates of phenotypic resistance 
against ciprofloxacin for the population.  
 
In the K. pneumoniae population, all isolates belonging to the three most dominant MLSTs 
(ST307, ST340 and ST15) carried genes for aminoglycoside- and quinolone-resistance in 
addition to several different ESBL enzymes, suggesting these genes may have been transferred 
collectively. 
 
The phylogenetic tree, constructed from the K. pneumoniae isolates, showed one large cluster 
of nine isolates. All these isolates were closely related. They all came from blood cultures, they 
were all ST307 and they all produced a CTX-M-15, an SHV-28 and carried the aac(6’)-Ib-cr 
gene. These isolates came from five different laboratories from different parts of the country, 
indicating that they do not represent an outbreak. The domination of this clone and the close 
clonal relation between the different isolates, suggest, like the ST131, that this clone is likely 
to have successfully established itself in the K. pneumoniae population and is now the 
dominating sequence type in clinical isolates in Norway. But as discussed previously in this 
chapter, we know nothing of its dissemination among carrier isolates, genomic analysis of 
carriage isolates is needed to address this issue. There were also two smaller clusters, each 
consisting of three isolates. One of them (the green cluster) consisted of isolates that all came 
from blood cultures, but from three different laboratories. These all belonged to ST15, they all 
had a CTX-M-15 and the aac(6’)-Ib-cr gene, and they seemed to ascend from the same strain. 
The third (blue) cluster, were all ST340 and they all produced a CTX-M-15 and the aac(6’)-Ib-
cr gene. Two of these isolates came from the same laboratory (Tromsø) while the third came 
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from Fredrikstad. These two clusters also indicate that isolates belonging to both these sequence 
types are descendants from two distinct strains. However, these sequence types are only 
represented by three isolates each, which is a very limited basis for determining the population 
structure of these sequence types. 
 
Among the K. pneumoniae isolates, there was one isolate highly unrelated to the rest of the 
population. This isolate belonged to ST334 and it harboured an SHV-12 ESBL, and in addition 
possessed an OKP-B-4-like b-lactamase. This isolate is most likely a K. quasipneumoniae 
(KpII), as it is unrelted to the rest of the isolates and carries a blaOKP, which is chromosomally 
encoded in this species [114]. Because these three subspecies of K. pneuomoniae are so similar, 
conventional identification systems like MALDI TOF MS, are not able to differentiate between 
the different species. Isolates belonging to any of these species will therefore only be identified 
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6 Conclusion 
The results of this study showed a prevalence of fecal carriage of K. pneumoniae among adults 
in Tromsø, to be 14.7 %, which is lower than other similar studies. However, there are some 
differences in study design, and especially the choice of screening-media could account for 
some of the differences. 
 
The study further showed a prevalence of fecal carriage of ESBL-producing E. coli and K. 
pneumoniae among the same population to be 3.2%. This rate is lower than most other 
investigated studies, which means the carriage rate of ESBL-producing E. coli and K. 
pneumoniae is lower in Norway, than in many other European countries. 
 
The genotypic characterization of the ESBL-producing E. coli isolates from Tromsø-7, revealed 
a dominance of ST131, with CTX-M-14, CTX-M-15 and CTX-M-27 production, among the 
isolates. The same sequence type was seen to dominate the clinical ESBL-producing E. coli 
isolates from NORM 2014, except among these isolates CTX-M-15 alone was by far the most 
dominating ESBL. Phylogenetic analysis also revealed the carrier strains and the clinical strains 
to be closely relaSTted, likely disseminated from one common strain. This suggests ST131 has 
established itself as the dominating ST in both clinical and carrier ESBL-producing E. coli. 
 
The genotypic characterization of the ESBL-producing K. pneumoniae isolates from NORM-
2014, showed ST307 to be the dominating sequence type. The phylogenetic analysis also 
revealed these isolates were clonally related as well. It is in this study not possible to determine 
if these findings are reflected in the community carriage of ESBL-producing K. pneumoniae as 
we did not perform WGS analysis of the carriage isolates.  
 
These results show there is still a low carriage rate of ESBL-producing K. pneumoniae and E. 
coli in Norway. However, high virulence strains are dominating in carriage of both species, 
which is a concerning development. This study further shows that surveillance of not only the 
rate of ESBL-producers, but also the population structure of these isolates should be performed 
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Table 1-A: Media, reagents and solutions used in this project. 
0.85 % NaCl: 
8,5 g Natrium chloride (Merck) 
ddH2O to 1 litre 
 
SCAI agar plates: 
Myo-inositol (Sigma-Aldrich) 





Brain Heart Infusion (Oxoid) 
Glycerol 85% (Merck) 
ddH2O 
 
CHROMagar ESBL plates: 
CHROMagar Orientation (CHROMagar) 




Lactose agar plates: 
Tryptose Blood Agar Base (Oxoid) 
Lactose (Oxoid) 
Bromthymol blue solution 0,2 % (Merck) 
ddH2O 
HCl (1M and 5M) (Sigma-Aldrich) 
 
 
CHROMagar mSuperCarba plates: 
CHROMagar mSuperCarba base 
CHROMagar mSuperCarba supplement S1 
CHROMagar mSuperCarba supplement S2 
ddH2O 
 
Lactose agar plates with 100 mg/ml 
ampicillin: 
Tryptose Blood Agar Base (Oxoid) 
Lactose (Oxoid) 
Bromthymol blue solution 0,2 % (Merck) 
ddH2O 
HCl (1M and 5M) (Sigma-Aldrich) 
Ampicillin 100mg/ml (Bristol-Myers Squibb) 
 
 
CLED agar plates: 
CLED medium (MAST) 
ddH2O 
NaOH (1 M) (Merck) 
Mueller-Hinton agar: 
Mueller-Hinton agar (Oxoid) 
ddH2O 
 
MALDI TOF matrix: 
HCC, portioned, matrix for MALDI TOF 




Proteinase K, recombinant, PCR grade 
(Roche).  
Consist of lyophilizate from Pichia pastoris 




Lyophilizate of lysozyme from chicken egg 
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EasyMAG extraction buffers: 
NucliSens easyMAG extraction buffer 1 
NucliSens easyMAG extraction buffer 2  
NucliSens easyMAG extraction buffer 3 
(Biomerieux) 
 
EasyMAG lysis buffer: 
NucliSens easyMAG lysis buffer 
(Biomerieux) 
 
EasyMAG silica beads: 
NucliSens easyMAG Magnetic Silica 
(Biomerieux) 
dsDNA HS Assay Kit for Qubit: 
Concentrated assay reagent 
Dilution buffer 
Pre-diluted DNA standards 
(Thermo Fisher Scientific) 
 
Recipe for the production of SCAI agar plates: 
 
 
1. Make a 10% solution of myo-inositol by dissolving 10g myo-inositol powder in 
100ml purified water. 
2. Make the simmons citrate agar by suspending 21g simmons citrate agar powder to 1L 
purified water. Mix thoroughly 
3. Heat the mixture and boil for 1 minute to completely dissolve the powder. 
4. Dispense and autoclave at 121°C for 20 minutes. 
5. Cool to 45-55°C  
6. Add 100ml of the myo-inositol suspension and add it to 900 ml of the simmons citrate 
agar, this will give the desired concentration of 1%. 





Setup of the two Sensititre broth dilution plates (NONAG4 and NONAG5): 
 
 
Figure 34: Specifications for the NONAG4 Sensititre plate with antimicrobial agents and concentrations for each 
well. 
 








Table 1-B: WGS data on ESBL-producing E. coli and K. pneumoniae from NORM 2014. 
WGS results:  ESBL-producing E. coli and K. pneumoniae – NORM 2014 














QnrB QnrS QnrVC qepA 
P19
_75 
E. coli BLC Haukeland ST-10 blaCTX-
M-15 




E. coli Urine Haukeland ST-10 blaCTX-
M-14 
        blaTEM-1B             
P19
_81 
E. coli Urine Haukeland ST-10 blaCTX-
M-15 
                      
P20
_57 
E. coli BLC Trondheim ST-10 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_33 




        blaOXA-1   aac(6')Ib-cr         
P20
_80 




                      
P20
_10 
E. coli BLC Lillehammer ST-410 blaCTX-
M-15 






  aac(6')Ib-cr   QnrS1     
P19
_21 
E. coli BLC AHUS ST-131 blaCTX-
M-1 
        blaTEM-1B             
P20
_08 
E. coli BLC Levanger ST-131 blaCTX-
M-1 
        blaTEM-1B             
P20
_58 
E. coli BLC Trondheim ST-131 blaCTX-
M-1 
        blaTEM-1B             
P21
_25 




                  
P19
_52 
E. coli BLC Fredrikstad ST-131 blaCTX-
M-14 
        blaTEM-1B             
P20
_14 
E. coli BLC Lillehammer ST-131 blaCTX-
M-14 
        blaTEM-1B             
P20
_44 
E. coli BLC Tromsø ST-131 blaCTX-
M-14 
        blaTEM-1B             
P20
_45 
E. coli BLC Tromsø ST-131 blaCTX-
M-14 
                      
P20
_72 
E. coli BLC Tønsberg ST-131 blaCTX-
M-14 
        blaTEM-1B             
P20
_73 
E. coli BLC Tønsberg ST-131 blaCTX-
M-14 
                      
P20
_78 
E. coli Urine Tønsberg ST-131 blaCTX-
M-14 







E. coli BLC Lillehammer ST-131 blaCTX-
M-14-like 
        blaTEM-1B             
P19
_14 
E. coli BLC AHUS ST-131 blaCTX-
M-15 
        blaTEM-1B             
P19
_19 
E. coli BLC AHUS ST-131 blaCTX-
M-15 
                      
P19
_20 
E. coli BLC AHUS ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_27 
E. coli BLC Bodø ST-131 blaCTX-
M-15 
        blaTEM-1B             
P19
_28 
E. coli BLC Bodø ST-131 blaCTX-
M-15 
        blaTEM-1B             
P19
_29 
E. coli BLC Bodø ST-131 blaCTX-
M-15 
        blaTEM-1B             
P19
_42 
E. coli BLC Drammen ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_43 
E. coli BLC Drammen ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_44 
E. coli BLC Drammen ST-131 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P19
_45 
E. coli BLC Drammen ST-131 blaCTX-
M-15 
                      
P19
_47 
E. coli Urine Drammen ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_50 
E. coli BLC Fredrikstad ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_51 
E. coli BLC Fredrikstad ST-131 blaCTX-
M-15 
        blaTEM-1B             
P19
_54 
E. coli BLC Fredrikstad ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_59 
E. coli BLC Førde ST-131 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P19
_65 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_66 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P19
_67 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_68 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_69 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_70 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_71 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_72 
E. coli BLC Haukeland ST-131 blaCTX-
M-15 







E. coli BLC Haukeland ST-131 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P19
_78 
E. coli Urine Haukeland ST-131 blaCTX-
M-15 
        blaTEM-1B             
P19
_79 
E. coli Urine Haukeland ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_17 
E. coli Urine Lillehammer ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_18 
E. coli BLC Molde ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_25 




        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P20
_30 
E. coli BLC Stavanger ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_32 
E. coli Urine Stavanger ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_54 
E. coli Urine Tromsø ST-131 blaCTX-
M-15 
                      
P20
_60 
E. coli BLC Trondheim ST-131 blaCTX-
M-15 
        blaTEM-1B             
P20
_67 
E. coli BLC Tønsberg ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_79 
E. coli Urine Tønsberg ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P21
_11 
E. coli BLC Ullevål ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P21
_21 
E. coli Urine Ullevål ST-131 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B-like 
  aac(6')Ib-cr         
P21
_24 
E. coli Urine Ullevål ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P21
_29 
E. coli BLC Ålesund ST-131 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_16 
E. coli BLC AHUS ST-131 blaCTX-
M-24 
        blaTEM-1B             
P21
_23 
E. coli Urine Ullevål ST-131 blaCTX-
M-24 
        blaTEM-1B             
P19
_22 
E. coli BLC AHUS ST-131 blaCTX-
M-27 
                      
P19
_36 
E. coli BLC Bærum ST-131 blaCTX-
M-27 
                      
P19
_38 
E. coli Urine Bærum ST-131 blaCTX-
M-27 
        blaTEM-1B     QnrB
1-like 
      
P19
_53 
E. coli BLC Fredrikstad ST-131 blaCTX-
M-27 
                      
P19
_55 
E. coli BLC Fredrikstad ST-131 blaCTX-
M-27 
                      
P19
_63 
E. coli BLC Haugesund ST-131 blaCTX-
M-27 







E. coli BLC Haugesund ST-131 blaCTX-
M-27 
            aac(6')Ib-
cr-like 
        
P19
_80 
E. coli Urine Haukeland ST-131 blaCTX-
M-27 
                      
P20
_29 
E. coli BLC Stavanger ST-131 blaCTX-
M-27 
                      
P20
_41 
E. coli BLC Tromsø ST-131 blaCTX-
M-27 
        blaTEM-1B             
P20
_65 
E. coli BLC Tønsberg ST-131 blaCTX-
M-27 
                      
P20
_69 
E. coli BLC Tønsberg ST-131 blaCTX-
M-27 
        blaTEM-1B             
P20
_70 
E. coli BLC Tønsberg ST-131 blaCTX-
M-27 
                      
P21
_01 
E. coli Urine Tønsberg ST-131 blaCTX-
M-27 
                      
P21
_06 
E. coli BLC Ullevål ST-131 blaCTX-
M-27 
                      
P21
_08 
E. coli BLC Ullevål ST-131 blaCTX-
M-27 
                      
P21
_20 
E. coli Urine Ullevål ST-131 blaCTX-
M-27 
                      
P20
_40 
E. coli BLC Tromsø ST-131 blaCTX-
M-27 
                      
P19
_18 
E. coli BLC AHUS ST-156 blaCTX-
M-14 
        blaOXA-10   aac(6')Ib-
cr-like 









        blaTEM-1B             
P20
_47 
E. coli BLC Tromsø ST-773 blaCTX-
M-14 
        blaTEM-1B             
P19
_58 
E. coli BLC Førde ST-345 blaCTX-
M-14b-
like 
        blaTEM-1B             
P20
_04 
E. coli Urine Kristiansand ST-14 blaCTX-
M-15 
        blaTEM-1B             
P21
_22 




        blaTEM-1B             
P19
_15 
E. coli BLC AHUS ST-192 blaCTX-
M-15 
        blaTEM-1B             
P20
_21 




                      
P20
_66 
E. coli BLC Tønsberg ST-372 blaCTX-
M-14 
                      
P21
_04 
E. coli BLC Ullevål ST-372 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1A 
  aac(6')Ib-cr         
P20
_11 
E. coli BLC Lillehammer ST-38 blaCTX-
M-15 











                      
P21
_07 
E. coli BLC Ullevål ST-38 blaCTX-
M-14 
                      
P21
_10 
E. coli BLC Ullevål ST-38 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P21
_13 




        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P21
_14 
E. coli BLC Ullevål ST-38 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P21
_33 
E. coli BLC Kristiansand ST-38 blaCTX-
M-14 
                      
P19
_37 
E. coli BLC Bærum ST-405 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_76 
E. coli BLC Haukeland ST-405 blaCTX-
M-15 
                      
P20
_05 
E. coli Urine Kristiansand ST-405 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_24 




        blaOXA-1   aac(6')Ib-cr         
P20
_37 
E. coli Urine Telelab ST-405 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_43 
E. coli BLC Tromsø ST-405 blaCTX-
M-14 
            aac(6')Ib-
cr-like 
        
P20
_46 
E. coli BLC Tromsø ST-405 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_59 
E. coli BLC Trondheim ST-405 blaCTX-
M-55 
        blaOXA-1 armA aac(6')Ib-cr         
P20
_64 
E. coli BLC Tønsberg ST-405 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P20
_68 
E. coli BLC Tønsberg ST-405 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P19
_34 
E. coli Urine Bodø ST-636 blaCTX-
M-15 




        
P21
_02 
E. coli Urine Tønsberg ST-69 blaCTX-
M-15 
        blaTEM-1B-like             
P21
_05 
E. coli BLC Ullevål ST-73 blaCTX-
M-15 
        blaTEM-1B     QnrB
66-
like 
      
P19
_40 
E. coli Urine Bærum ST-617 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr         
P19
_60 
E. coli BLC Førde ST-617 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1C 







E. coli Urine Tromsø ST-88 blaCTX-
M-15 
        blaTEM-1B             
P19
_24 
E. coli Urine AHUS ST-648 blaCTX-
M-15 
        blaOXA-1   aac(6')Ib-cr QnrB
66-
like 
      
P20
_13 
E. coli BLC Lillehammer ST-648 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P20
_81 
E. coli Urine Tønsberg ST-648 blaCTX-
M-14 
        blaTEM-1B             
P21
_15 
E. coli BLC Ullevål ST-648 blaCTX-
M-15 
                      
P21
_26 
E. coli Urine Ullevål ST-648 blaCTX-
M-14 
                      
P21
_31 
E. coli Urine Ålesund ST-648 blaCTX-
M-15 
        blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr         
P20
_63 
E. coli Urine Trondheim ST-648 blaCTX-
M-2 
              QnrB
19 
      
P19
_17 
E. coli BLC AHUS ST-977 blaCTX-
M-15 
        blaTEM-1B             
P20
_48 




        blaOXA-1             
P19
_35 




                      
P20
_61 
E. coli BLC Trondheim ST-127 blaCTX-
M-55 
        blaTEM-1B             
P20
_09 
E. coli BLC Lillehammer ST-95 blaCTX-
M-15, 
    blaIMP-26   blaTEM-1B-like armA aac(6')Ib-
cr-like 
        
P21
_12 
E. coli BLC Ullevål ST-95 blaCTX-
M-55 






Urine Ullevål ST-101 blaCTX-
M-15 























      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 










      blaTEM-1B     QnrB
66-
like 


























      blaTEM-1B, 
blaOXA-1-like 
  aac(6')Ib-cr QnrB
66-
like 














      blaOXA-
1,blaOXA-10-
like,blaTEM-1B 












      blaOXA-
1,blaTEM-1B 






Urine Kristiansand ST-16 blaCTX-
M-15 
        blaOXA-
1,blaSHV-
1,blaTEM-1B 






Urine Haukeland ST-231 blaCTX-
M-15 
        blaSHV-
1,blaTEM-1B-like 






Urine Haukeland ST-231 blaCTX-
M-15 
        blaOXA-
1,blaSHV-
1,blaTEM-1B-like 






Urine Haukeland ST-273   blaSH
V-2-
like 
    blaDHA-
1 
blaOXA-1   aac(6')Ib-cr QnrB
4 










      blaTEM-
1B,blaOXA-1 
  aac(6')Ib-cr QnrB
66-
like 










      blaTEM-
1B,blaOXA-1 
  aac(6')Ib-cr QnrB
66-
like 










      blaOXA-1, 
blaTEM-1B 












      blaOXA-
1,blaTEM-1B 










      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 










      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 










      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 










      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 










      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 











      blaTEM-1B     QnrB
66-
like 










BLC Lillehammer ST-334   blaSH
V-12 
      blaOKP-B-4-like     QnrB
1 












    blaOXA-1 armA aac(6')Ib-cr QnrB
66-
like 




















      blaOXA-
1,blaOXA-10 











      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 











      blaOXA-
1,blaTEM-1B 
    QnrB
66-
like 











      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 































      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
1-like 






Urine Stavanger ST-45   blaSH
V-12 










      blaTEM-1B     QnrB
66-
like 






BLC Tønsberg ST-627  blaSH
V-2 











      blaOXA-
1,blaTEM-1B 
  aac(6')Ib-cr QnrB
66-
like 






Urine Fredrikstad ST-904  blaSH
V-2-
like 
                    
P20
_06 
E. coli Urine Kristiansand ST-155  blaSH
V-12 
            QnrB
7 











            QnrB
19 











































Table 2-B: WGS data on ESBL-producing E. coli and K. pneumoniae from Tromsø-7. 
WGS results:  ESBL-producing E. coli and K. pneumoniae – Tromsø-7 
ID Species Sample mat. Laboratory ST CTX-M ESBL SHV-ESBL Carbapenemase pAmpC Other β-lactamases  16S methylase aac(6')Ib-cr 
50918404 E. coli Feces Tromsø ST-10 blaCTX-M-15       blaOXA-1   aac(6')Ib-cr 
50932514 E. coli Feces Tromsø ST-12 blaCTX-M-14             
50937543 E. coli Feces Tromsø ST-12 blaCTX-M-14             
50930986 E. coli Feces Tromsø ST-1290 blaCTX-M-14       blaTEM-1A     
50923324 E. coli Feces Tromsø ST-131 blaCTX-M-15       blaOXA-1   aac(6')Ib-cr 
50925997 E. coli Feces Tromsø ST-131 blaCTX-M-27       blaTEM-1B     
50927790 E. coli Feces Tromsø ST-131 blaCTX-M-27       blaTEM-1B     
50930924 E. coli Feces Tromsø ST-131 blaCTX-M-14             
50929669 E. coli Feces Tromsø ST-131         blaTEM-1B-like     
50931575 E. coli Feces Tromsø ST-131 blaCTX-M-15       blaTEM-1B     
50938355 E. coli Feces Tromsø ST-131 blaCTX-M-14       blaTEM-1B     
50938698 E. coli Feces Tromsø ST-2178 blaCTX-M-15       blaTEM-1B     
50929164 E. coli Feces Tromsø ST-38 blaCTX-M-14       blaTEM-1B     
50932516 E. coli Feces Tromsø ST-448 blaCTX-M-15       blaTEM-1B     
50937429 E. coli Feces Tromsø ST-450 blaCTX-M-14             
50929679 E. coli Feces Tromsø ST-617 blaCTX-M-15             
50930927 E. coli Feces Tromsø ST-648 blaCTX-M-15       blaOXA-1,blaTEM-1B   aac(6')Ib-cr 
50921884 E. coli Feces Tromsø ST-69 blaCTX-M-15       blaTEM-1B     
50929671 E. coli Feces Tromsø ST-88         blaOXA-1     
50931574 E. coli Feces Tromsø ST-93 blaCTX-M-8             
50922842 E. coli Feces Tromsø Unknown         blaTEM-1B-like     
50937533 E. coli Feces Tromsø Unknown blaCTX-M-15       blaTEM-1B     
50934266 K.pneumoniae Feces Tromsø ST-46         blaSHV-1     
 
